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A B S T R A C T
Background
In many low- and middle-income countries (LMICs) morbidity and mortality associated with cardiovascular diseases (CVDs) have
grown exponentially over recent years. It is estimated that about 80% of CVD deaths occur in LMICs. People in LMICs are more
exposed to cardiovascular risk factors such as tobacco, and often do not have access to effective and equitable healthcare services
(including early detection services). Evidence from high-income countries indicates that multiple risk factor intervention programmes
do not result in reductions in CVD events. Given the increasing incidence of CVDs and lower CVD health awareness in LMICs it is
possible that such programmes may have beneficial effects.
Objectives
To determine the effectiveness of multiple risk factor interventions (with or without pharmacological treatment) aimed at modifying
major cardiovascular risk factors for the primary prevention of CVD in LMICs.
Search methods
We searched (from inception to 27 June 2014) theCochrane Library (CENTRAL, HTA, DARE, EED),MEDLINE, EMBASE, Global
Health and three other databases on 27 June 2014. We also searched two clinical trial registers and conducted reference checking to
identify additional studies. We applied no language limits.
Selection criteria
We included randomised controlled trials (RCTs) of health promotion interventions to achieve behaviour change (i.e. smoking cessation,
dietary advice, increasing activity levels) with or without pharmacological treatments, which aim to alter more than one cardiovascular
risk factor (i.e. diet, reduce blood pressure, smoking, total blood cholesterol or increase physical activity) of at least six months duration
of follow-up conducted in LMICs.
1Multiple risk factor interventions for primary prevention of cardiovascular disease in low- and middle-income countries (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Data collection and analysis
Two authors independently assessed trial eligibility and risk of bias, and extracted data. We combined dichotomous data using risk
ratios (RRs) and continuous data using mean differences (MDs), and presented all results with a 95% confidence interval (CI). The
primary outcome was combined fatal and non-fatal cardiovascular disease events.
Main results
Thirteen trials met the inclusion criteria and are included in the review. All studies had at least one domain with unclear risk of bias.
Some studies were at high risk of bias for random sequence generation (two trials), allocation concealment (two trials), blinding of
outcome assessors (one trial) and incomplete outcome data (one trial). Duration and content of multiple risk factor interventions
varied across the trials. Two trials recruited healthy participants and the other 11 trials recruited people with varying risks of CVD,
such as participants with known hypertension and type 2 diabetes. Only one study reported CVD outcomes and multiple risk factor
interventions did not reduce the incidence of cardiovascular events (RR 0.57, 95% CI 0.11 to 3.07, 232 participants, low-quality
evidence); the result is imprecise (a wide confidence interval and small sample size) and makes it difficult to draw a reliable conclusion.
None of the included trials reported all-cause mortality. The pooled effect indicated a reduction in systolic blood pressure (MD -
6.72 mmHg, 95% CI -9.82 to -3.61, I² = 91%, 4868 participants, low-quality evidence), diastolic blood pressure (MD -4.40 mmHg,
95% CI -6.47 to -2.34, I² = 92%, 4701 participants, low-quality evidence), body mass index (MD -0.76 kg/m², 95% CI -1.29 to
-0.22, I² = 80%, 2984 participants, low-quality evidence) and waist circumference (MD -3.31, 95% CI -4.77 to -1.86, I² = 55%,
393 participants, moderate-quality evidence) in favour of multiple risk factor interventions, but there was substantial heterogeneity.
There was insufficient evidence to determine the effect of these interventions on consumption of fruit or vegetables, smoking cessation,
glycated haemoglobin, fasting blood sugar, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol and
total cholesterol. None of the included trials reported on adverse events.
Authors’ conclusions
Due to the limited evidence currently available, we can draw no conclusions as to the effectiveness of multiple risk factor interventions
on combined CVD events and mortality. There is some evidence that multiple risk factor interventions may lower blood pressure
levels, body mass index and waist circumference in populations in LMIC settings at high risk of hypertension and diabetes. There was
considerable heterogeneity between the trials, the trials were small, and at some risk of bias. Larger studies with longer follow-up periods
are required to confirm whether multiple risk factor interventions lead to reduced CVD events and mortality in LMIC settings.
P L A I N L A N G U A G E S U M M A R Y
Concurrent health promotion interventions for preventing cardiovascular disease in low- and middle income countries (“re-
source-limited settings”)
Review question
This review examines the effectiveness of health promotion interventions that aim to reduce more than one major cardiovascular risk
factor (multiple risk factor intervention) for the primary prevention of cardiovascular disease in low- and middle-income countries
(LMICs). Such risk factors are overweight/obesity, high blood pressure, smoking, too much bad cholesterol or low physical activity
levels.
Background
Evidence from high-income countries indicates that multiple risk factor intervention programmes do not result in reductions in
cardiovascular disease (CVD) events. Given the increasing incidence of CVDs and lower CVD health awareness in LMICs it is possible
that such programmes may have beneficial effects. One vital element in improving this situation is a comprehensive and relevant
evidence base, which would equip LMICs to take informed action. The components of health promotion activities may include the
following: (a) dietary advice to promote healthy eating habits; (b) reducing harmful alcohol intake; (c) advice on the cessation of
cigarette smoking; (d) advice on increasing daily physical activity; and (e) reducing body weight.
Study characteristics
We performed a thorough search of the medical literature up to June 2014. We identified 13 trials that recruited 7310 participants. Two
trials recruited healthy participants and the other 11 trials recruited people at varying risk of CVD, such as participants with known
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hypertension(“high blood pressure”) and type 2 diabetes, and randomly assigned them to either a multiple risk factor intervention
or to no intervention. The trials were conducted between 2001 and 2010, and published between 2004 and 2012. Three trials were
conducted in Turkey. Two trials each were conducted in China and Mexico. One trial recruited participants from both China and
Nigeria. The other trials were conducted in Brazil, India, Pakistan, Romania and Jordan. The content of the interventions varied across
the trials; most of the trials included dietary advice and advice on physical activity. The trials follow-up the participants between six
months to 30 months (average follow-up period was 13.3 months).
Key results
We found that evidence for effects on cardiovascular disease events was scarce, with only one trial reporting these. None of the included
trials reported deaths from any cause. Multiple risk factors interventions may lower systolic blood pressure, diastolic blood pressure,
body mass index and waist circumference. We found no difference for eating more fruit and vegetables, rates of smoking cessation,
measure of blood glucose sugar was for the past two to three months, fasting blood sugar, high density lipoprotein (HDL) cholesterol,
low density lipoprotein (LDL) cholesterol and total cholesterol. None of the included trials reported on harms.
Quality of the evidence
Overall, the studies included in this review were at some risk of bias and there was variation between the results of the studies when we
analysed the data. Our findings should be treated with some caution.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Multiple risk factor interventions for primary prevention of cardiovascular disease in low- and middle-income countries
Patient or population: people with primary prevention of cardiovascular disease in
Settings: Low- and middle-income countries
Intervention: Multiple risk factor interventions
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Control Multiple risk factor interven-
tions
Cardiovascular event 32 per 1000 18 per 1000
(4 to 99)
RR 0.57
(0.11 to 3.07)
232
(1 study)
⊕⊕©©
low1
Systolic
blood pressure, change from
baseline (mmHg)
The mean change from base-
line in systolic blood pressure
was -8.69 mmHg
The mean systolic blood pres-
sure, change from baseline
(mmHg) in the intervention
groups was
6.72 lower
(9.82 to 3.61 lower)
4868
(11 studies)
⊕⊕©©
low2
Diastolic
blood pressure, change from
baseline (mmHg)
The mean change from base-
line in diastolic blood pressure
was -4.96 mmHg
The mean diastolic blood
pressure, change from base-
line (mmHg) in the interven-
tion groups was
4.4 lower
(6.47 to 2.34 lower)
4701
(11 studies)
⊕⊕©©
low2
Body mass index, change
from baseline (kg/m2)
The mean change from base-
line in body mass index was -
0.94 kg/m2
The mean body mass index,
change from baseline (kg/m2)
in the intervention groups was
0.76 lower
(1.29 to 0.22 lower)
2984
(7 studies)
⊕⊕©©
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Waist circumference,
change from baseline (cm)
The mean change from base-
line in waist circumference
was -3.68 cm
The mean waist circumfer-
ence, change from base-
line (cm). in the intervention
groups was
3.31 lower
(4.77 to 1.86 lower)
393
(4 studies)
⊕⊕⊕©
moderate3
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1The effect estimate is limited by the small sample size of the study and wide confidence interval for the effect estimate
2Inconsistency rated very serious as there was moderate heterogeneity in treatment effect estimates (I² >75%).
3Inconsistency rated serious as there was considerable heterogeneity in treatment effect estimates (I² >50%).
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B A C K G R O U N D
Description of the condition
Non-communicable diseases (or chronic diseases), are not trans-
mitted from person to person and are of slow progression (Hunter
2013; WHO 2015a). The four main types of non-communicable
disease are cardiovascular disease, cancer, chronic respiratory dis-
ease and diabetes (Hunter 2013;WHO 2015a). In many low- and
middle-income countries (LMICs) the morbidity and mortality
associated with non-communicable diseases have grown exponen-
tially over recent years (WHO 2005; WHO 2011). It is estimated
that about 80% of non-communicable disease deaths occur in
LMICs, which is a reflection of both the size of this population and
epidemiological changes (WHO 2005; WHO 2011). In 2010,
it was estimated that most non-communicable diseases-associated
deaths occurred before 60 years of age, and that the preponder-
ance of these deaths occurred in LMICs (Lim 2012). LMICs are
now experiencing epidemiological transition, the change from a
burden of infectious diseases to chronic diseases (Gaziano 2010),
due to dramatic changes in diet and lifestyle. The epidemiological
transition in LMICs is happening in a shorter time frame than
that experienced historically by high-income countries (Miranda
2008). Urbanisation and consumption of unhealthy diets are the
main causes of this epidemic in LMICs (BeLue 2009; Miranda
2008;WHO 2011). In addition, LMICs are not only dealing with
the emerging burden of non-communicable diseases, but also the
current burden of infectious diseases (Perel 2006; Reddy 2004;
Yusuf 2001a; Yusuf 2001b).
Cardiovascular diseases account for most non-communicable dis-
ease deaths, or 17.3 million people annually, followed by cancers
(7.6 million), respiratory diseases (4.2 million) and diabetes (1.3
million) (Lim 2012). It is estimated that these four groups of dis-
eases account for around 80% of all non-communicable disease
deaths and they share four risk factors: tobacco use, physical in-
activity, the harmful use of alcohol, and unhealthy diets (Ezzati
2013; Lim 2012). ’Cardiovascular diseases’ is a term for a group
of diseases of blood vessels and the heart. The following are the
major types of cardiovascular disease: cerebrovascular disease, con-
genital heart disease, and coronary heart disease (WHO 2015b).
While people in LMICs are now exposed to increased intermedi-
ate cardiovascular risks, such as tobacco use, they have less access
to preventive programmes and effective healthcare needs (WHO
2015b).
Description of the intervention
Multiple risk factor interventions (health promotion activities) are
defined as interventions that address more than one cardiovascular
disease risk factor at the same time, in addition to, or instead of,
pharmacological treatments, in order to modify major cardiovas-
cular risk factors. The components of multiple risk factor inter-
ventions include, but are not limited to, the following: (a) dietary
advice to modify the individual’s eating habits in order to reduce
the percentage of calories from saturated fats, decrease the dietary
cholesterol intake, and increase the percentage of calories from
polyunsaturated fats; (b) reducing harmful alcohol intake; (c) ad-
vice on the cessation of cigarette smoking; (d) advice on increas-
ing daily physical activity; and (e) reducing body weight (Benfari
1981; Davey 2005; Kornitzer 1985). Since the incidence of car-
diovascular disease is mainly explained by the presence of modi-
fiable risk factors (blood lipid levels, blood pressure and cigarette
smoking), reducing these risk factors through health promotion
that focuses on lifestyles is a logical way to prevent cardiovascular
disease. However, current evidence suggests that these interven-
tions do not result in lower CVD events (Ebrahim 2011).
Therapeutic lifestyle modification, including increasing physical
activity, changing eating habits and eliminating addictions, has
been seen as a cornerstone of therapy for managing people with
metabolic syndrome (Márquez-Celedonio 2009), a clinical en-
tity characterised by a constellation of metabolically relevant ab-
normalities, and cardiovascular risk factors, including obesity, in-
sulin resistance/glucose intolerance, dyslipidaemia and hyperten-
sion (Grundy 2005; Magkos 2009). Several intervention trials
have reported the effects of lifestyle intervention programmes
among high-risk groups (Ebrahim 2011; Mattila 2003; Muto
2001; Nilsson 2001). Lifestyle modifications have been shown
to decrease the incidence of type 2 diabetes mellitus by 58%
among people with impaired glucose intolerance (Knowler 2002;
Tuomilehto 2001) and significantly lowered systolic blood pres-
sure between -5.4 to -11.4 mmHg (Baena 2014). Therapeutic
lifestyle interventions have been found to be at least as effective as
pharmacotherapies (Gillies 2007), at little cost andwithminimum
risk (Appel 1997). In contrast tomost pharmacotherapies, lifestyle
modifications can also prevent or control other chronic conditions
(Knowler 2002; Stamler 1989). However, it has been suggested
that in order for therapeutic lifestyle modification to be effective,
it is important to pay attention not only to one single cardiovas-
cular risk factor but to several factors simultaneously (Tuomilehto
2011). It is therefore generally recommended that lifestyle modi-
fications should be implemented as a group (JNC-VII 2003).
How the intervention might work
The majority of the models of health behaviour change that are
currently used as a basis for multiple risk factor interventions for
preventing cardiovascular disease are derived from traditional cog-
nitive theory (Bandura 1977a). They include the health belief
model (Maimen 1974), health promotion model (Pender 1988),
theory of reasoned action (Ajzen 1980; Ajzen 1985; Ajzen 1991),
theory of planned behaviour (Ajzen 1980; Ajzen 1985; Ajzen
1991), self-efficacy theory (Bandura 1977), and the ’stages of
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change’model (Norcross 2011; Prochaska 1979; Prochaska 1983).
The theory of planned behaviour proposes that a person’s inten-
tion to perform a behaviour is the immediate determinant of
that behaviour, as it reflects the level of motivation a person is
willing to exert to perform the behaviour (Ajzen 1991). Another
widely applied cognitive model is the ’stages of change’ model
(also referred to as the transtheoretical model) (Chouinard 2007;
Mochari-Greenberger 2010; Salmela 2009). The transtheoretical
model subdivides individuals into five categories (Norcross 2011;
Prochaska 1979; Prochaska 1983); these represent different mile-
stones or ’levels of motivational readiness’ along a continuum of
behaviour change (Heimlich 2008). These stages are: (i) precon-
templation (the individual is unaware of the problem and there is
no intention to change behaviour in the foreseeable future); (ii)
contemplation (the individual is aware of the problem and there
is a serious consideration of change in behaviour); (iii) prepara-
tion (the individual is willing to take action); (iv) actionable (the
individual modifies their behaviour, experiences or environment
or both in order to overcome the problem); and (v) maintenance
(the individual works to prevent relapse and consolidate gains).
The Isfahan Healthy Heart Program (IHHP) is a comprehen-
sive, integrated, community-based programme for cardiovascu-
lar disease prevention and control, aiming to reduce cardiovas-
cular disease risk factors and improve cardiovascular health be-
haviour among Iranians (Sarraf-Zadegan 2003). The IHHP ad-
vocated prevention and control of high blood pressure and dia-
betes, healthy eating patterns to lower cholesterol, non-smoking
and regular physical activity. Sarraf-Zadegan 2003 reported that
the prevalence of abdominal obesity, hypertension, hypercholes-
terolaemia andhypertriglyceridaemia decreased significantly in the
intervention areas compared with reference areas in both sexes.
Jeemon 2012, using a non-randomised comparison, examined
the impact of a comprehensive cardiovascular risk reduction pro-
gramme on risk factor clustering associated with elevated blood
pressure, using a sentinel surveillance study in an Indian industrial
population (SSIP), using a population-based approach (Jeemon
2012; Prabhakaran 2009; Reddy 2006). The components of the
SSIP intervention included: “1) workplace-organised individual
and group counselling sessions, health displays, cooking compe-
titions and dance classes; 2) posters, banners, handouts, booklets
and real-time videos with simple, captivating messages translated
into seven Indian languages for health education; 3) initiation
of changes by management and employees (e.g. increasing salads
and decreasing salty and fried foods on canteen menus, and en-
forcing smoking bans); and 4) identifying high-risk individuals
through screening who were referred to the on-site health facili-
ties for risk management (individual and group counselling was
also offered)” (Jeemon 2012). The results of the SSIP programme
showed that a comprehensive cardiovascular disease risk reduction
programme significantly reduced the cardiovascular risk burden,
the proportion of participants with high blood pressure, and risk
factors decreased from 10.6% to 4.7% in the intervention group
but increased from 13.3% to 17.8% in the no-intervention group
(Jeemon 2012).
Why it is important to do this review
A comprehensive Cochrane review has examined the effectiveness
of multiple risk factor interventions in all settings, predominantly
high-income countries (Ebrahim 2011). It pooled data from 14
trials that randomised 139,256 participants and reported clinical
event endpoints. Ebrahim 2011 found that “counselling and edu-
cation interventions designed to change health behaviours do not
reduce total or coronary heart disease mortality or clinical events
in general populations, but they may be effective in reducing mor-
tality in high-risk hypertensive and diabetic populations”. The
Ebrahim review, in which most studies were based in high-income
countries, concluded that health promotion interventions have
limited use in general populations. Caution is needed in general-
ising evidence from high-income countries to the current LMIC
context because of the differences in settings and the nature of the
communities, as well as the targeted populations.
O B J E C T I V E S
To determine the effectiveness of multiple risk factor interventions
(with or without pharmacological treatment) aimed at modifying
major cardiovascular risk factors for the primary prevention of car-
diovascular disease in low- andmiddle-income countries (LMICs).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We include randomised controlled trials (RCTs) of at least six
months duration of follow-up, conducted in LMICs. The trials’
randomisation units could either be individuals or clusters (such
as family, workplace site). We only include trials conducted in
LMICs as defined in the World Bank Country Income Groups at
the time of the trial’s data collection (World Bank 2014).
Types of participants
Adult populations (≥ 18 years of age). We include workforce pop-
ulations, population-based studies that include high-risk groups
(such as hypertension, obesity, hyperlipidaemia, type 2 diabetes or
a combination of these) or individuals without high risk of devel-
oping cardiovascular disease.
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We exclude trials where there is evidence that more than 25% of
the participants have diagnosed cardiovascular disease at baseline.
As with previous systematic review on multiple risk factor inter-
ventions, our cut-off was 25% (Ebrahim 2011).
Types of interventions
Health promotion interventions to achieve behaviour change, such
as smoking cessation, dietary advice, increasing activity levels, with
or without pharmacological treatments, which aim to alter more
than one cardiovascular risk factor including: diet, blood pressure,
smoking, total blood cholesterol or physical activity.
Comparison: no intervention for the control group.
Types of outcome measures
Primary outcomes
1. Combined fatal and non-fatal cardiovascular disease events
(including myocardial infarction, unstable angina, need for
coronary bypass grafting or percutaneous coronary intervention,
stroke, peripheral artery disease)
2. Adverse events
Secondary outcomes
1. All cause-mortality
2. Changes in cardiovascular disease risk factors (blood
pressure, lipid levels, diabetes, and obesity)
3. Changes in health knowledge, attitudes and intention
Search methods for identification of studies
Electronic searches
We identified trials through systematic searches of the following
bibliographic databases (from inception to 27 June 2014):
• Cochrane Central Register of Controlled Trials
(CENTRAL, Issue 5 of 12, 2014) in the Cochrane Library;
• MEDLINE (Ovid, 1946 to June week 3 2014);
• EMBASE Classic + EMBASE (Ovid, 1947 to 2014 June
26);
• Science Citation Index Expanded (SCI-EXPANDED, 1970
to 25 June 2014) and Conference Proceedings Citation Index -
Science (CPCI-S, 1990 to 25 June 2014) on Web of Science
(Thomson Reuters);
• Database of Abstracts of Reviews of Effects (DARE, Issue 2
of 4, 2014) in the Cochrane Library;
• Health Technology Assessments (HTA, Issue 2 of 4, 2014)
in the Cochrane Library;
• Economic Evaluation Database (EED, Issue 2 of 4, 2014)
in the Cochrane Library;
• LILACS (Bireme);
• Global Health (OVID, 1910 to 2014 week 25);
• ELDIS (www.eldis.org).
We adapted the preliminary search strategy forMEDLINE (Ovid)
for use in the other databases (Appendix 1). We applied the
Cochrane sensitivity-maximising RCT filter to the MEDLINE
(Ovid) strategy and adaptations of it to the other databases (except
CENTRAL) (Lefebvre 2011).
We also searched the following clinical trial registries for trials that
are near completion or completed but yet to be published:
1. Clinicaltrials (www.clinicaltrials.gov), search terms “(health
promotion OR healthy lifestyle) AND cardiovascular disease”
(searched on 4 July 2014)
2. WHO International Clinical Trials Registry Platform (
apps.who.int/trialsearch/), search terms “(health promotion OR
healthy lifestyle) AND cardiovascular disease” (searched on 4
July 2014)
We did not impose any restriction on language of publication.
Searching other resources
We checked the reference lists of all primary studies and review
articles for additional references.
Data collection and analysis
Selection of studies
Two authors (OAU and LH) independently screened the titles
and abstracts of all the potential studies we identified as a result
of the search, and coded them as ’retrieve’ (eligible or potentially
eligible/unclear) or ’do not retrieve’. In case of any disagreements,
we asked a third author (KR) to arbitrate. We retrieved the full-
text study reports/publications and two authors (OAU and LH)
independently screened these to identify studies for inclusion. We
identified and recorded reasons for the exclusion of ineligible stud-
ies. We resolved any disagreements through discussion or, if re-
quired, we consulted a third author (KR). We identified and ex-
cluded duplicates and collate multiple reports of the same study,
so that each study rather than each report is the unit of interest in
the review. We recorded the selection process in sufficient detail to
complete a PRISMA flow diagram (Figure 1) and ’Characteristics
of excluded studies’ table.
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Figure 1. Study flow diagram.
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Data extraction and management
We used a data collection form for study characteristics and out-
come data, which had been piloted on at least one study in the
review. One author (OAU) extracted study characteristics from
the included studies. We extracted the following characteristics:
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and location, study
setting, withdrawals and date of study.
2. Participants: number, mean age, age range, gender, severity
of condition, diagnostic criteria, baseline measures of
physiological functioning (e.g. cardiovascular function, blood
pressure, body mass index, blood glucose, HbA1C, smoking
history), inclusion and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial and notable conflicts of interest of
trial authors.
Two authors (OAU and LH) independently extracted outcome
data from the included studies. We noted in the ’Characteristics
of included studies’ table if outcome data were not reported in
a usable way. We resolved disagreements by consensus or by in-
volving a third author (KR). One author (OAU) transferred data
into the Review Manager 5 software (RevMan 2014). We double-
checked that data had been entered correctly by comparing the
data presented in the systematic review with the study reports. A
second author (LH) spot-checked study characteristics for accu-
racy against the trial report.
Assessment of risk of bias in included studies
Two authors (OAUandLH) independently assessed risk of bias for
each study using the criteria outlined in theCochraneHandbook for
Systematic Reviews of Interventions (Higgins 2011).We resolved any
disagreements by discussion or by involving another author (KR).
We assessed the risk of bias according to the following domains.
1. Random sequence generation
2. Allocation concealment
3. Blinding of outcome assessment
4. Incomplete outcome data
5. Selective outcome reporting
6. Other bias
We graded each potential source of bias as high, low or unclear, and
provide a quote from the study report together with a justification
for our judgement in the ’Risk of bias’ tables. We summarised the
’Risk of bias’ judgements across different studies for each of the
domains listed.
For cluster-randomised trials, we assessed the following cluster-
specific risks of bias as outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011).
1. Recruitment bias - whether the individuals participating in
the trial were blinded to the type of cluster they were in before
agreeing to participate
2. Baseline imbalance - whether there were differences in
baseline characteristics between the randomised groups
3. Loss of clusters - whether any complete clusters were lost to
follow-up and the reasons
4. Incorrect analysis - whether the proper statistical analysis
was carried out for a cluster-randomised design
5. Comparability with individually randomised trials -
whether the cluster-randomisation method could have resulted
in different intervention effects than an individually-randomised
trial
When considering treatment effects, we took into account the risk
of bias of the studies that contribute to that outcome.
Assessment of bias in conducting the systematic review
We conducted the review according to its published protocol
(Uthman 2014) and reported any deviations from it in the
’Differences between protocol and review’ section of the review.
Measures of treatment effect
Weused ReviewManager 5 tomanage the data and to conduct the
analyses. We reported dichotomous outcomes as risk ratios (RRs)
with 95% confidence intervals (CIs). For continuous outcomes,
we calculated mean differences (MDs) with 95% CIs when the
studies use the same scale.
Unit of analysis issues
Cluster-randomised trials
We included cluster-randomised trials in the meta-analysis along
with individually-randomised trials. Cluster-randomised trials are
labelled with a (C). For cluster-randomised trials to be included in
the meta-analyses, we adjusted for design effect using an ‘approx-
imation method’ (Higgins 2011). The ’approximation method’
entailed calculation of an ’effective sample size’ for the comparison
groups by dividing the original sample size by the ’design effect’,
which is 1 + (M− 1) ICC, where M is the average cluster size and
ICC is the intracluster correlation coefficient. For dichotomous
data, we divided both the number of participants and the number
who experienced the event by the same design effect, while for
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continuous data, only the sample size was reduced (means and
standard deviations (SDs) were left unchanged). We used the fol-
lowing reported (Mendis 2010 (C)) ICCs for calculating the ’de-
sign effects’: systolic blood pressure: ICC 0.04; average cluster size
(M): 59.92; design effect (DE) 3.36; and diastolic blood pressure:
ICC 0.06; M: 59.92; DE: 4.54.
Studies with more than two treatment groups
For studies with more than two intervention groups (multi-arm
studies), we included only the directly relevant arms. When we
identified studies with various relevant arms, we combined the
groups into a single pairwise comparison (Higgins 2011) and in-
cluded the disaggregated data in the corresponding subgroup cat-
egory.
Cross-over trials
We did not accept cross-over trials.
Dealing with missing data
We contacted investigators or study sponsors in order to verify key
study characteristics and obtain missing numerical outcome data
where possible (e.g. when a study is identified as an abstract only).
Assessment of heterogeneity
We used the I² statistic to measure heterogeneity among the trials
in each analysis (Higgins 2003). When we identified substantial
heterogeneity (I² value greater than 50%), i.e. more than 50% of
the variation is due to heterogeneity rather than chance (Schroll
2011), we reported it and explored possible causes by prespecified
subgroup analysis.
Assessment of reporting biases
We used funnels plots and Egger tests (Egger 1997) to assess po-
tential small-study biases and publication bias for those outcomes
with more than 10 trials (i.e. systolic and diastolic blood pressure).
Data synthesis
We summarised and analysed all eligible studies in Review Man-
ager 5. Two authors (OU and LH) extracted the data; the first au-
thor entered all data and the second author checked all entries. We
resolved disagreements by discussion. We undertook meta-analy-
ses only where this was meaningful, i.e. if the treatments, partici-
pants and the underlying clinical question were similar enough for
pooling to make sense. We combined the data using a random-ef-
fects model, due to anticipated heterogeneity that may result from
the differences in methodology and study settings.
Subgroup analysis and investigation of heterogeneity
We planned the following subgroups:
• High-risk groups (known diabetes, hypertension) compared
with healthy/general population
• Low-income countries compared with low-middle-income
countries
Sensitivity analysis
We planned to use sensitivity analysis to explore heterogeneity.
• Method of randomisation (clustered; clustered analyses as
individual; individual).
’Summary of findings’ table
We assessed the quality of evidence of the primary outcomes using
the GRADE approach (Guyatt 2008) and present the results in
the ’Summary of findings’ table. The GRADE system considers
‘quality’ to be a judgement of the extent to which we can be con-
fident that the estimates of effect are correct. The level of ‘quality’
is judged on a four-point scale:
1. High quality: Further research is very unlikely to change
our confidence in the estimate of effect.
2. Moderate quality: Further research is likely to have an
important impact on our confidence in the estimate of effect and
may change the estimate.
3. Low quality: Further research is very likely to have an
important impact on our confidence in the estimate of effect and
is likely to change the estimate.
4. Very low quality: We are very uncertain about the estimate.
We initially graded evidence from RCTs as high, and downgraded
it by either one, two, or three levels after full consideration of:
any limitations in the design of the studies, the directness (or
applicability) of the evidence, the consistency and precision of the
results, and the possibility of publication bias.
R E S U L T S
Description of studies
Results of the search
The literature searches yielded 13,468 titles of potentially relevant
articles after duplicates were removed. After scanning titles and ab-
stracts, we identified 413 potentially relevant articles and assessed
full-text copies against the inclusion criteria. Of these, 13 RCTs
met the inclusion criteria. Details of the flow of studies through
the review are given in Figure 1.
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Included studies
Details of the methods, participants, intervention, comparison
group and outcome measures for each of the included studies in
the review are provided in the Characteristics of included studies
table.
We included 13 trials (Avram 2011; Cakir 2006; Chao 2012;
Garcia-Peña 2001; Hacihasanoglu 2011; Hammad 2011; Jafar
2009 (C); Kisioglu 2004; Lu 2011; Márquez-Celedonio 2009;
Mendis 2010 (C); Sartorelli 2005; Snehalatha 2008). Where this
was reported, the trials were conducted between 2001 and 2010,
and published between 2004 and 2012. Three trials were con-
ducted in Turkey (Cakir 2006; Hacihasanoglu 2011; Kisioglu
2004). Two trials each were conducted in China (Chao 2012;
Lu 2011) and Mexico (Garcia-Peña 2001; Márquez-Celedonio
2009).One trial recruited participants frombothChina andNige-
ria (Mendis 2010 (C)). The other trials were conducted in Brazil
(Sartorelli 2005), India (Snehalatha 2008), Pakistan (Jafar 2009
(C)), Romania (Avram 2011) and Jordan (Hammad 2011).
Unit of randomisation
The randomisation unit for most trials was individual partici-
pants (Avram 2011; Cakir 2006; Chao 2012; Garcia-Peña 2001;
Hacihasanoglu 2011; Hammad 2011; Kisioglu 2004; Lu 2011;
Márquez-Celedonio 2009; Sartorelli 2005; Snehalatha2008). Two
trials used cluster randomisation (primary care facilities (Mendis
2010 (C)) and households (Jafar 2009 (C)).
Trial participants:
Only two trials (Chao 2012; Kisioglu 2004) recruited partici-
pants from healthy or general population. Most trials (n = 11) re-
cruited high-risk groups: known hypertensive people (Cakir 2006;
Garcia-Peña 2001; Hacihasanoglu 2011; Jafar 2009 (C); Mendis
2010 (C)); pre-hypertensive people (Márquez-Celedonio 2009);
metabolic syndrome (Avram 2011; Hammad 2011); obese partic-
ipants (Sartorelli 2005); and people with impaired glucose regu-
lation (Lu 2011; Snehalatha 2008).
Intervention content:
The content of the interventions varied across the trials (see Table
1). Most of the trials included dietary advice and advice on phys-
ical activity. The follow-up period ranged from six months to 30
months (mean 13.3 months).
Excluded studies
We present details and reasons for exclusion for the studies that
most nearly missed the inclusion criteria in the Characteristics of
excluded studiestable.
Risk of bias in included studies
Wepresent details for each of the included trials in the ’Risk of bias’
tables in the Characteristics of included studies, and summaries in
Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The generation of allocation sequence was adequate in four trials
(Cakir 2006; Chao 2012; Hammad 2011; Jafar 2009 (C)), un-
clear in seven trials (Garcia-Peña 2001; Kisioglu 2004; Lu 2011;
Márquez-Celedonio 2009; Mendis 2010 (C); Sartorelli 2005;
Snehalatha 2008) and inadequate in two trials (Avram 2011;
Hacihasanoglu 2011). Avram 2011 andHacihasanoglu 2011 used
the calendar date for generating allocation sequence. Allocation
concealment was adequate in one trial (Cakir 2006) , inadequate
in two trials (Avram 2011; Hacihasanoglu 2011) and unclear in
the remaining 10 trials.
Blinding
Four trials (Avram 2011; Cakir 2006; Jafar 2009 (C); Kisioglu
2004) masked outcome assessors to treatment allocation and one
trial (Hacihasanoglu 2011) did not. It is not clear whether the
remaining trialsmasked outcome assessors to treatment allocation.
Incomplete outcome data
The potential risk of bias likely to be introduced by incomplete
data was high in only one trial (Sartorelli 2005), unclear in three
trials (Avram 2011; Mendis 2010 (C); Snehalatha 2008), low in
the remaining nine trials.
Selective reporting
The risk of selective reporting bias was unclear in Avram 2011,
and low in the remaining 12 trials.
Other potential sources of bias
The risk of bias likely to be introduced by other potential sources
of bias was low in two trials (Jafar 2009 (C); Mendis 2010 (C))
and unclear in the remaining 11 trials.
Overall, the studies included in this review were at some risk of
bias. All studies had at least one domain with unclear risk of bias,
and some studies were at high risk of bias for random sequence
generation (two trials: Avram 2011; Hacihasanoglu 2011), alloca-
tion concealment (two trials: Avram 2011; Hacihasanoglu 2011),
blinding of outcome assessors (Hacihasanoglu 2011) and incom-
plete outcome data (Sartorelli 2005).
Cluster-specific risks of bias
We present details for each of the included trials in Figure 4. The
risk of bias due to recruitment bias was low in one trial (Jafar 2009
(C)) and unclear in one trial (Mendis 2010 (C)). Baseline charac-
teristics were generally similar in the two cluster trials. No com-
plete clusters were lost to follow-up in the two trials. Jafar 2009
(C) accounted for the clustering effect in the main analysis while
Mendis 2010 (C) did not. It is not clear whether the cluster-ran-
domisation method could have resulted in different intervention
effects than an individually-randomised trial in the two cluster
trials.
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Figure 4.
Effects of interventions
See: Summary of findings for the main comparison Multiple
risk factor interventions for primary prevention of cardiovascular
disease in low- and middle-income countries
Primary outcomes:
Combined Cardiovascular events
One trial (Snehalatha 2008) reported cardiovascular events as an
outcome.Therewas no significant difference between intervention
and control groups in the rates of cardiovascular events (RR 0.57,
95% CI 0.11 to 3.07, 232 participants) (Analysis 1.1). This result
is imprecise (wide confidence interval and small sample size) and
makes it difficult to draw a reliable conclusion.
Adverse events
None of the included trials reported on adverse events.
Secondary outcomes:
All-cause mortality
None of the included trials reported all-cause mortality.
Changes in cardiovascular risk factors
Blood pressure
Systolic blood pressure and diastolic blood pressure were reported
in 11 trials (5106 participants randomised) (Cakir 2006; Chao
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2012; Garcia-Peña 2001; Hacihasanoglu 2011; Hammad 2011;
Jafar 2009 (C); Lu 2011;Márquez-Celedonio 2009;Mendis 2010
(C); Sartorelli 2005; Snehalatha 2008). The pooled effect showed
a statistically significant reduction in systolic blood pressure (MD
-6.72mmHg, 95%CI -9.82 to -3.61, 4868 participants) (Analysis
1.2) in favour of multiple risk factors interventions, but with ev-
idence of statistically significant substantial between-trial hetero-
geneity (I² = 91%, P = 0.0001). There was no evidence of funnel
plot asymmetry for systolic blood pressure (SBP) (Figure 5), sug-
gesting no evidence of small-study bias (P = 0.270 for Egger’s re-
gression asymmetry test). In a prespecified subgroup analysis, the
pooled intervention effect estimate tended to bemore pronounced
among high-risk groups (MD -7.14, 95% CI -11.07 to -3.21, 10
trials, 2906 participants) than in the general population (MD -
3.95, 95% CI -5.20 to -2.70, one trial, 1962 participants); how-
ever, this difference did not reach a statistically significant level (P
= 0.13 for interaction). Sensitivity analysis showed that the bene-
ficial effect of a multiple risk factor intervention on SBP was only
significant among trials that randomised individual participants
(MD -8.02 mmHg, 95% CI -11.79 to -4.24, 3549 participants)
and not in trials that randomised clusters of participants (MD -
1.65, 95% CI -6.52 to 3.22, 1319 participants) (P = 0.04 for in-
teraction).
Figure 5. Funnel plot of comparison: 1 Multiple risk factor interventions, outcome: 1.2 Systolic blood
pressure, change from baseline (mmHg).
Similarly, the pooled effect showed a statistically significant reduc-
tion in diastolic blood pressure (DBP) (MD -4.40 mmHg, 95%
CI -6.47 to -2.34, 4701 participants) (Analysis 1.4) in favour of
multiple risk factors interventions, but with evidence of statisti-
cally significant substantial between-trial heterogeneity (I² = 92%,
P = 0.0001). There was no evidence of funnel plot asymmetry
for diastolic blood pressure (Figure 6), suggesting no evidence of
small-study bias (P = 0.446 for Egger’s regression asymmetry test).
In a prespecified subgroup analysis, the pooled intervention effect
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estimate tended to be more pronounced among high-risk groups
(MD -4.55, 95% CI -7.26 to -1.85, 10 trials, 2739 participants)
than in the general population (MD -3.18, 95% CI -3.90 to -
2.46, one trial, 1962 participants); however, this difference did
not reach a statistically significant level (P = 0.34 for interaction).
Kisioglu 2004 found no statistically significant difference between
intervention and control groups in the rate of high blood pres-
sure (RR 0.87, 95% CI 0.54 to 1.40, 400 participants). Sensitiv-
ity analysis showed that the beneficial effect of multiple risk fac-
tor interventions on DBP was only significant among trials that
randomised individual participants (MD -5.29 mmHg, 95% CI -
7.65 to -2.94, 3549 participants) and not in trials that randomised
clusters of participants (MD -0.70, 95% CI -3.79 to 2.40, 1152
participants) (P = 0.02 for interaction).
Figure 6. Funnel plot of comparison: 1 Multiple risk factor interventions, outcome: 1.4 Diastolic blood
pressure, change from baseline (mmHg).
Anthropometric indices
Body mass index (BMI) was reported in seven trials (Cakir 2006;
Chao 2012; Hacihasanoglu 2011; Lu 2011; Márquez-Celedonio
2009; Mendis 2010 (C); Sartorelli 2005). The pooled effect
showed a statistically significant reduction in BMI (MD -0.76 kg/
m², 95% CI -1.29 to -0.22, 2984 participants) (Analysis 1.6) in
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favour of multiple risk factors interventions, but with evidence of
statistically significant substantial between-trial heterogeneity (I²
= 80%, P = 0.00003). However, this effect was only significant
among the high-risk groups (MD -0.94 kg/m², 95% CI -1.54 to
-0.33, six trials, 1022 participants) and not among the general
population (MD -0.14 kg/m², 95% CI -0.47 to 0.19, one trial,
1962 participants). Waist circumference was reported in four tri-
als (Cakir 2006; Lu 2011; Márquez-Celedonio 2009; Snehalatha
2008). The pooled effect showed a statistically significant reduc-
tion in waist circumference (MD -3.31, 95% CI -4.77 to -1.86, I²
= 55%, four trials, 393 participants) (Analysis 1.7). Kisioglu 2004
found a significantly reduced rate of obesity in the intervention
group compared with the control group (RR 0.71, 95% CI 0.52
to 0.97, 400 participants).
Fasting blood sugar
Six trials reported fasting blood sugar as an outcome (Chao 2012;
Hammad 2011; Lu 2011; Márquez-Celedonio 2009; Sartorelli
2005; Snehalatha 2008). There was no statistically significant dif-
ference between intervention and control in mean change from
baseline fasting blood glucose (MD -0.22 mmol/L, 95% CI -0.56
to 0.13, 2726 participants) (Analysis 1.8).
Glycated haemoglobin (haemoglobin A1c)
One trial (Lu 2011) reported glycated haemoglobin as an out-
come. There was no statistically significant difference between the
intervention and control groups in mean change from baseline
percentage HbA1c (MD -0.08%, 95% CI -0.38 to 0.22, 181 par-
ticipants).
Blood lipids
Six trials reported on blood lipids (Cakir 2006; Hammad 2011;
Lu 2011; Márquez-Celedonio 2009; Sartorelli 2005; Snehalatha
2008). There were no statistically significant differences between
intervention and control in mean change from baseline high den-
sity lipoprotein (HDL) cholesterol (MD 0.03 mmol/L, 95% CI -
0.01 to 0.07, 824 participants) (Analysis 1.9), low density lipopro-
tein (LDL) cholesterol (MD -0.13mmol/L, 95%CI -0.53 to 0.27,
four trials, 544 participants) (Analysis 1.9) and total cholesterol
(MD -0.22 mmol/L, 95%CI -0.48 to 0.04, five trials, 625 partici-
pants) (Analysis 1.9). There was a small but statistically significant
reduction in triglycerides with multiple risk factor interventions
of -0.14 mmol/L (95% CI -0.23 to -0.04, six trials, 2705 partici-
pants) (Analysis 1.10).
Changes in health knowledge, attitudes and intention.
Fruits and vegetables consumption
One trial (Mendis 2010 (C)) (2166 participants randomised) re-
ported increased fruit and vegetable consumption as an outcome.
At site B (Nigeria), participants in the intervention group showed a
significantly greater increase in fruit consumption (RR 5.02, 95%
CI 3.40 to 7.40, P = 0.0001, 247 participants) and a non-signifi-
cant increase in vegetable consumption (RR 2.00, 95%CI 0.91 to
4.40, P = 0.08, 247 participants) compared to the control group.
However, in site A (China), there was no significant difference be-
tween the intervention and control groups in the number of those
that increased fruit consumption (RR 1.03, 95% CI 0.77 to 1.39,
P = 0.83, 301 participants) and vegetable consumption (RR 0.88,
95% CI 0.53 to 1.46, P = 0.62, 301 participants) compared with
the control group.
Smoking cessation
One trial (Mendis 2010 (C)) (2166 participants randomised) re-
ported smoking cessation as an outcome. There was no signifi-
cant difference between the intervention and control groups in the
number of those that stopped smoking at both sites: Site A (China:
RR 2.08, 95% CI 0.19 to 23.21, P = 0.55, 301 participants) and
Site B (Nigeria: RR 0.62, 95% CI 0.21 to 1.83, P = 0.38, 247
participants).
D I S C U S S I O N
Summary of main results
This review of multiple risk factor interventions for primary pre-
vention of cardiovascular disease in low- andmiddle-income coun-
tries (LMICs) has brought together evidence from 13 randomised
controlled trials primarily from the last 10 years, incorporating
7310 participants. We found that evidence for effects on CVD
events was scarce, with only one trial reporting these. We found
that multiple risk factor interventions have an effect on some risk
factors, especially on systolic blood pressure, diastolic blood pres-
sure, body mass index and waist circumference. However, the risk
factor changes associated with interventions should be interpreted
with caution. The meta-analyses of risk factor changes were highly
heterogeneous, making pooled estimates of effect questionable.
Furthermore, there are many problems in relating trial outcome to
a risk measure which is itself dependent on the outcome in meta-
analysis (Egger 1995).
Overall completeness and applicability of
evidence
The majority of the trials included in our review recruited par-
ticipants who were at varying levels of CVD risk. Only one trial
provided usable data on the general population. In addition, only
18Multiple risk factor interventions for primary prevention of cardiovascular disease in low- and middle-income countries (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
one small trial of the effect of multiple risk factor interventions on
cardiovascular events reported our primary outcome, combined
fatal and non-fatal CVD events (including myocardial infarction,
unstable angina, need for coronary bypass grafting or percutaneous
coronary intervention, stroke, peripheral artery disease). The re-
sult for the CVD events is imprecise (a wide confidence interval
and small sample size) as this outcome was reported by only a
single small study, underpowered to detect differences. This small
trial lacks statistical power and makes it difficult to draw a reliable
conclusion.
Quality of the evidence
Overall, the studies included in this review were at some risk of
bias, and the results should be treated with caution. We assessed
the quality of the evidence in this review using the GRADE ap-
proach, and present the evidence in Summary of findings for the
main comparison. For cardiovascular events, systolic blood pres-
sure, diastolic blood pressure and body mass index we judged the
quality of evidence to be low, reflecting that further research is very
likely to have an important impact on our confidence in the esti-
mate of effect and is likely to change the estimate.We downgraded
the evidence for cardiovascular events by two levels for very serious
imprecision. The quality of evidence for the primary outcome of
cardiovascular events was limited by the small sample size of the
study and a wide confidence interval for the effect estimate. For
systolic blood pressure, diastolic blood pressure and body mass
index, we downgraded the evidence by two levels for very serious
inconsistency because of considerable heterogeneity in treatment
effect estimates (I² > 75%). We graded the quality of evidence for
waist circumference as moderate, suggesting that further research
is likely to have an important impact on our confidence in the
estimate of effect and may change the estimate. We downgraded
the evidence for mean change waist circumference by one level for
serious inconsistency because of moderate heterogeneity in treat-
ment effect estimates (I² > 50%). We found statistically signif-
icant heterogeneity in all the meta-analyses of changes in CVD
risk factors, thus suggesting that the percentage of the variability
in effect estimates that is due to heterogeneity rather than to sam-
pling error (chance) is important. The heterogeneity may be due
to differences in study follow-up, geographical location, baseline
differences in blood pressure values and content of the multiple
risk factor interventions.
Potential biases in the review process
We conducted a comprehensive search across major databases for
multiple risk factor interventions. We also screened systematic re-
view reference lists and we contacted trial authors when necessary.
Two authors independently carried out all screening, inclusion
and exclusion and data abstraction, and conducted data entry and
analysis. It is unlikely that the methods used in the review could
have introduced bias.
Agreements and disagreements with other
studies or reviews
Ebrahim 2011 conducted a Cochrane review to assess the effects
of multiple risk factor interventions for reducing total mortality,
fatal and non-fatal coronary heart disease (CHD) events and car-
diovascular risk from factoring, among adults assumed to be with-
out clinical evidence of prior CHD. The review included 55 trials
that enrolled 163,471 participants and found that “interventions
using counselling and education aimed at behaviour change do
not reduce total or CHD mortality or clinical events in general
populations but may be effective in reducing mortality in high-
risk hypertensive and diabetic populations” (Ebrahim 2011). An-
other recent systematic review (Baena 2014) examined the effects
of lifestyle-related interventions on blood pressure in LMICs. The
review included eightmultiple-intervention trials (defined asmore
than one lifestyle-related intervention delivered at the same time)
and found that the studies combining physical activity and diet or
behavioural counselling interventions significantly reduced both
the SBP (pooledMD -6.1 mmHg, 95% CI -8.9 to -3.3) and DBP
(pooled MD -2.4 mmHg, 95% CI -3.7 to -1.1) (Baena 2014).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Due to the limited evidence available, currently we can draw no
conclusions as to the effectiveness of multiple risk factor interven-
tions on combined CVD events and mortality. Risk factor mod-
ification programmes may be effective in altering risk factors in
people living in LMICs. However, the evidence comes from stud-
ies at some risk of bias and there was statistical variation between
the results of the studies.
Implications for research
There is a paucity of randomised controlled trials looking at the
effects of multiple risk factor interventions for the primary pre-
vention of CVD events and mortality over the long term. There
is therefore a need for well-designed randomised controlled trials
to fill this research gap. Further research is also needed to identify
which components of multiple risk factor interventions, which
modes of delivery and which settings are key for an effective mul-
tiple risk factor programme.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Avram 2011
Methods Randomised controlled trial
Randomisation unit: individual
Participants Setting: participants from EuroAspire III Romania
253 high-risk individuals (on anti-hypertensive drug therapy and/or lipid-lowering drug
therapy and/or anti-diabetes therapies) under 80 years, without a history of coronary or
other atherosclerotic disease, who met the revised NCEP-ATPIII criteria for MetSyn:
waist circumference > 102 cm in men, > 88 cm in women; elevated triglycerides: ≥ 1.7
mmol/L (≥ 150 mg/dL); low HDL- cholesterol < 1.03 mmol/L (< 40 mg/dL) in men,
< 1.29 mmol/L (< 50 mg/dL) in women; systolic blood pressure ≥ 130 mmHg and/or
diastolic blood pressure≥ 85mmHg, or treatment of previously diagnosed hypertension;
impaired fasting plasma glucose ≥ 5.6 mmol/L (≥ 100 mg/dL) or previously diagnosed
type 2 diabetes
N umber of participants : 253; Intervention (n=133), Control (120)
Interventions “Each subject in the intervention was offered a total of approximately 90 min of inter-
vention contacts in 3 consecutive visits (every 6 months) to general practitioner (GP)
offices, consisting in lifestyle habits in relation to diet, weight control and physical ac-
tivity. Beside this, once a month the patients received a follow- up phone from their GP,
emphasis was placed on weight loss, decreasing fat intake, portion control and healthier
food group selection along with increasing in daily physical activity”
Outcomes Changes in health knowledge, attitudes and intention (physical activity, intention to
loose weight)
Maximum follow-up: 18 months
Notes Study period : Not reported
Sources of funding : Executive Agency for Higher Education, Research, Development
and Innovation Funding (UEFISCDI), Romania
Declared conflicts of interest of the trialists : None declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk ...randomisation by calendar date
Allocation concealment (selection bias) High risk Allocation not concealed
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The staff members who scheduled
the study visits and those who performed
the measurements were blind to random-
ization”
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Avram 2011 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to judge
Selective reporting (reporting bias) Unclear risk Insufficient information to judge
Other bias Unclear risk Insufficient information to judge
Cakir 2006
Methods Randomised controlled trial
Randomisation unit: individual
Participants Setting: University hospital, Instabul, Turkey
Personswere eligible if theywere between 18 and 65 years of age, had been diagnosedwith
hypertension (i.e., mean SBP of ≥ 140 mmHg and/or mean DBP of ≥ 90 mmHg on 3
separate occasions during a 3-week period), and were able to complete the questionnaire
unaided
N umber of participants : 60; Intervention (n=30), Control (n=30)
Interventions “The intervention group received a 30-minute lecture by a nurse on core knowledge
and information on the behavioural skills necessary to manage hypertension. In the first
month, two60-minute classeswere also held for groups of 6 to 8 participants. Participants
were provided with information and detailed guidelines, especially on the daily number
of servings from each of the six food groups (meats and protein, grains, vegetables, fruits,
dairy, and fats and oils) and the requisite amount of fat intake, sodium intake, alcohol
consumption, and physical activity
The diet recommendations were mainly based on the DASH diet, which emphasizes
fruits, vegetables, and low-fat dairy foods; includes whole grains, poultry, fish, and nuts;
and recommends smaller amounts of red meat, sweets, and sugar-containing beverages
The physical exercise goal of the lifestyle modification was 30 minutes of walking 3 days
per week. Participants who had not previously been physically active started with 20
minutes of walking per session and increased the duration of exercise during several weeks
until their goal was met. We followed a clinical practice guideline to help participants
who smoked to decrease tobacco use and dependence
Participants were encouraged to stop smoking and were given an appropriately planned
time in which to quit smoking (within 2 weeks)
The final educational class was held at the end of the 3rd month. The goal of the final
class was to maintain active behavioural changes among the participants and attempt to
reengage inactive participants.”
Outcomes Changes in CVD risk factors (blood pressure, lipid levels, anthropometric indices)
Maximum follow-up period: 6 months
Notes Study period : Not reported
Sources of funding : Not reported
Declared conflicts of interest of the trialists : None declared
Risk of bias
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Cakir 2006 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk computer-generated random numbers
Allocation concealment (selection bias) Low risk ... assigned centrally
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “A trained nurse took BP measure-
ments, and the trained nurse whomeasured
and recorded these BP results was blinded
to whether the participant belonged to the
intervention or the control group.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data were reasonably well balanced
between groups
Selective reporting (reporting bias) Low risk Primary and secondary outcomes were
clearly stated and reported
Other bias Unclear risk Insufficient information to judge
Chao 2012
Methods Randomised controlled trial
Randomisation unit: individual
Participants Setting : Nanjing Community Health Service Center
Healthy adults aged 60 and over
N umber of participants : 1962; Intervention (n=957), Control (n=1005)
Interventions “The intervention group received a healthmanagement program on diet advice, psycho-
logical aspects of health, a tailor-made exercise program based on an earlier evaluation,
education/skills training on health self-management, telephone consultation, lectures on
health, and distribution of health promoting materials. The components of the inter-
vention were ‘administered’ at least once per month by specifically-trained community
health service center staff, managers and related researchers”
Outcomes Changes in CVD risk factors (blood pressure, lipid levels, diabetes, obesity)
Maximum follow-up: 18 months
Notes Study period : November 2000 to September 2001
Sources of funding : Not reported
Declared conflicts of interest of the trialists : None declared
Risk of bias
Bias Authors’ judgement Support for judgement
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Chao 2012 (Continued)
Random sequence generation (selection
bias)
Low risk ..random number table
Allocation concealment (selection bias) Unclear risk Insufficient information to judge
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to judge
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data were reasonably well balanced
between groups
Selective reporting (reporting bias) Low risk Primary and secondary outcomes were
clearly stated and reported
Other bias Unclear risk Insufficient information to judge
Garcia-Peña 2001
Methods Randomised controlled trial
Randomisation unit: individual
Participants Setting : Family Medicine Centre run by the Institute in Mexico city
Participants with hypertension aged > 60 years
N umber of participants : 683; Intervention (n=345), Control (n=338)
Interventions “Participants in the intervention group received regular visits from a nurse over 6months.
During visits (between once amonth and fortnightly), the nursemeasured blood pressure
and the nurse and patient reviewed information from the baseline health check, and
discussed possible lifestyle changes. The nurses tried to guide their patients to a healthier
lifestyle and suggested different alternative ways to achieve the changes and negotiated
specific targets.”
Outcomes Changes in CVD risk factors (blood pressure)
Maximum follow-up: 6 months
Notes Study period : January 1998 to June 1999
Sources of funding : National Council of Science and Technology, Mexico (CONA-
CYT) and Mexican Institute of Social Security (IMSS)
Declared conflicts of interest of the trialists : None declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information to judge
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Garcia-Peña 2001 (Continued)
Allocation concealment (selection bias) Unclear risk Insufficient information to judge
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to judge
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data were reasonably well balanced
between groups
Selective reporting (reporting bias) Low risk Primary and secondary outcomes were
clearly stated and reported
Other bias Unclear risk Insufficient information to judge
Hacihasanoglu 2011
Methods Randomised controlled trial
Randomisation unit: individual
Participants Setting : Residents of Erzincan, Turkey
Hypertensive patients
N umber of participants : 80; Intervention (n=40), Control (n=40)
Interventions “The intervention group received six monthly nurse-led education on healthy lifestyle
behaviours (nutrition, relevant diet, importance of reduced salt intake, how to deal with
stress, weight control, exercise, risks of alcohol and smoking, etc.)”
Outcomes Changes in CVD risk factors (blood pressure, body mass index)
Maximum follow-up: 6 months
Notes Study period : February 2006 to November 2006
Sources of funding : Not reported
Declared conflicts of interest of the trialists : None declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk .. days of the week
Allocation concealment (selection bias) High risk allocation not concealed
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Allocation andoutcomes datawere
not blind”
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Hacihasanoglu 2011 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data were reasonably well balanced
between groups
Selective reporting (reporting bias) Low risk Primary and secondary outcomes were
clearly stated and reported
Other bias Unclear risk Insufficient information to judge
Hammad 2011
Methods Randomised controlled trial
Randomisation unit: individual
Participants Setting : Six family medicine clinics at Jordan University Hospital
People with metabolic syndrome as defined the NCEP/ATP III criteria
N umber of participants : 199; Intervention (n=110), Control (n=89)
Interventions “Pharmacists provided medication counselling for 30 minutes before seeing the physi-
cian, offered instructions on self-monitoring BP, and advised patients on healthy lifestyle
choices (e.g., tobacco cessation and adhering to a healthy diet). Educational materials
including brochures and pamphlets were provided to patients with information on the
recommended dietary approaches to stop hypertension (DASH). The pharmacist em-
phasized lifestyle changes, particularly weight loss and physical activity, as a first-line
therapy for at least 3 months.”
Outcomes Changes in CVD risk factors (blood pressure, lipid levels, anthropometric indices)
Maximum follow-up: 6 months
Notes Study period : March 2009 to may 2009
Sources of funding : Deanship of Research, The University of Jordan, Amman, Jordan.
Declared conflicts of interest of the trialists : None declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ... using a coin-toss method
Allocation concealment (selection bias) Unclear risk Insufficient information to judge
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to judge
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data were reasonably well balanced
between groups
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Hammad 2011 (Continued)
Selective reporting (reporting bias) Low risk Primary and secondary outcomes were
clearly stated and reported
Other bias Unclear risk Insufficient information to judge
Jafar 2009 (C)
Methods Cluster randomised trial
Randomisation unit: census-based clusters
Participants Setting: Communities in Karachi, Pakistan
Persons 40 years or older who resided in the 12 clusters and had known hypertension or
consistently elevated bloodpressure on2 separate visits (meanof 2 of past 3measurements
of SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg)
N umber of participants : 678; Intervention (n=348), Control (n=326)
Interventions “The intervention group received community health worker-led advice on diet and the
importance of engaging in moderate physical activity, maintaining normal body weight,
and tobacco cessation. The nutritional recommendations were modelled on the dietary
approaches to stop hypertension (DASH) diet. The first home health education session,
lasting 90 minutes, was held at a time when all members of the household were present.
Follow-up reinforcement visits of 30 minutes took place at three monthly intervals.”
Outcomes Changes in CVD risk factor (blood pressure)
Maximum follow-up : 24 months
Notes Study period : Not reported
Sources of funding : Wellcome Trust
Declared conflicts of interest of the trialists : None declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk computer-generated
Allocation concealment (selection bias) Unclear risk Insufficient information to judge
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Trained out-
comes assessors masked to randomisation
status evaluated all participants two years
after randomisation. The outcomes asses-
sors were not part of and had no relation-
ship with the baseline data collection or the
community health worker team.”
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Jafar 2009 (C) (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data were reasonably well balanced
between groups
Selective reporting (reporting bias) Low risk Primary and secondary outcomes were
clearly stated and reported
Other bias Low risk The study appears to be free of other source
of bias
Kisioglu 2004
Methods Randomised controlled trial
Randomisation unit: - individual
Participants Setting: poor outskirts of the city of Isparta, Turkey
Women of all ages
N umber of participants : 400; Intervention (n=200), Control (n=200)
Interventions The health promotion on significance of balanced nutrition, diverse assortment of food
and importance of physical exercise was delivered to women in groups of 5, the inter-
vention was conducted only 1 to 3 intervention programmes per day. Daily and regular
exercising, hiking, walking, or jogging were advised as having good health impact and
reducing stress, obesity, hypertension, and osteoporosis in women
Outcomes Changes in health knowledge, attitudes and intention
Maximum follow-up: 6 months
Notes Study period : August 2001 to September 2001
Sources of funding : Not reported
Declared conflicts of interest of the trialists : None declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information to judge
Allocation concealment (selection bias) Unclear risk Insufficient information to judge
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The investigators and assessors
were different independent persons, and
the staff participating in the study were not
the residents of Yenice and not related to
the subjects”
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Kisioglu 2004 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data were reasonably well balanced
between groups
Selective reporting (reporting bias) Low risk Primary and secondary outcomes were
clearly stated and reported
Other bias Unclear risk Insufficient information to judge
Lu 2011
Methods Randomised controlled trial
Randomisation unit: individual
Participants Setting: 4 communities of the Shijingshan District, China
Adults with impaired glucose regulation (IGR) using the 75 g OGTT
N umber of participants : 181; Intervention (n=95), Control (n=86)
Interventions “Participants in the intervention group received lifestyle intervention, including lectures
on diet and exercise given face-to-face once every 3 months and by telephone once per
month”
Outcomes Changes in CVD risk factors (blood pressure, lipid levels, diabetes, obesity)
Maximum follow-up: 12 months
Notes Study period : Not reported
Sources of funding : Not reported
Declared conflicts of interest of the trialists : None declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information to judge
Allocation concealment (selection bias) Unclear risk Insufficient information to judge
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to judge
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data were reasonably well balanced
between groups
Selective reporting (reporting bias) Low risk Primary and secondary outcomes were
clearly stated and reported
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Lu 2011 (Continued)
Other bias Unclear risk Insufficient information to judge
Mendis 2010 (C)
Methods Cluster-randomised trial
Randomisation unit: primary health care facilities
Participants Settings : 10 pairs of primary care facilities in China
Men and women 30 - 70 years of age with SBP between 140 and 179 mmHg were
selected for the study if they were not on treatment for hypertension and did not have
any exclusion factor
N umber of participants : 2397; Intervention (n=1114), Control (n=1042)
Interventions Participants in the intervention group were counselled on risk fact or control (tobacco
cessation, diet, physical activity) at baseline, 4 months, 8 months and 12 months
Outcomes Changes in CVD risk factors (blood pressure, obesity) and Changes in health knowledge
Maximum follow-up : 12 months
Notes Study period : 2005 to 2006
Sources of funding : Not reported
Declared conflicts of interest of the trialists : None declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information to judge
Allocation concealment (selection bias) Unclear risk Insufficient information to judge
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to judge
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to judge
Selective reporting (reporting bias) Low risk Primary and secondary outcomes were
clearly stated and reported
Other bias Low risk The study appears to be free of other source
of bias
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Márquez-Celedonio 2009
Methods Randomised controlled trial
Randomisation unit: individual
Participants Setting: Primary health care clinics in Mexico
Individuals with prehypertension, which is defined as a SBP between 120 mmHg and
139 mmHg and a DBP between 80 mmHg and 89 mmHg
N umber of participants : 81; Intervention (n=38), Control (n=43)
Interventions ”“Participants in the intervention group undertook a lifestyle modification program for
a period of 6 months: assigned a low-sodium, DASH-type diet; undertook 3-5 sessions
per week of aerobic physical exercise (walking, running, swimming) complemented by
group sport sessions (soccer, basketball, volleyball, or “cachibol” [a form of volleyball
often played by older persons]). Each session lasted 45 min, starting with stretching
exercises followed by 30 min of specific exercise and a recovery phase.”
Outcomes Changes in CVD risk factors (blood pressure, lipid levels, anthropometric indices, blood
sugar)
Maximum follow-up: 6 months
Notes Study period : Not reported
Sources of funding : No reported
Declared conflicts of interest of the trialists : None declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information to judge
Allocation concealment (selection bias) Unclear risk Insufficient information to judge
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to judge
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data were reasonably well balanced
between groups
Selective reporting (reporting bias) Low risk Primary and secondary outcomes were
clearly stated and reported
Other bias Unclear risk Insufficient information to judge
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Sartorelli 2005
Methods Randomised clinical trial
Randomisation unit: individual
Participants Setting: primary health-care centre in Brazil
High-risk groups such as overweight/obese adults or 1st-degree relatives of people with
type 2 diabetes
N umber of participants : 104; Intervention (n=51), Control (n=53)
Interventions “Subjects in the intervention group were scheduled for three individualised dietary coun-
selling sessions during the first 6 months of intensive lifestyle intervention and further
health checks at 6 months and 1 year from baseline. The intervention group received a
diet prescription provided by a nutritionist with a food exchange list and was encour-
aged to practise at least 30 min of walking per day. The dietary interventions included
increased intakes of olive oil, fruits (at least 2 servings day21), vegetables (at least 5 serv-
ings day21) and skimmed dairy products (2 or 3 servings day21), together with reduced
intake of saturated fat (<10% of energy by reducing red meat - less than 2 servings day)
and keeping the consumption of total fat around 30% of energy without emphasis on
total energy restriction.”
Outcomes Changes in CVD risk factors (blood pressure, lipid levels, diabetes, obesity)
Maximum follow-up: 12 months
Notes Study period : April 2000 ro March 2001
Sources of funding : São Paulo Research Foundation (FAPESP) and The Brazilian
National Council for Scientific and Technological Development (CNPq)
Declared conflicts of interest of the trialists : None declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information to judge
Allocation concealment (selection bias) Unclear risk Insufficient information to judge
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to judge
Incomplete outcome data (attrition bias)
All outcomes
High risk High dropout rates in control arm
Selective reporting (reporting bias) Low risk Primary and secondary outcomes were
clearly stated and reported
Other bias Unclear risk Insufficient information to judge
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Snehalatha 2008
Methods Randomised controlled trial
Randomisation unit: individual
Participants Setting: The Indian Diabetes Prevention Programme (IDPP)
IGT on 2 occasions (2-hr post-glucose levels > 7.8 to < 11.1 mmol/L)
N umber of participants : 232; Intervention (n=108), Control (n=124)
Interventions Participants in the intervention group received lifestyle modification (LSM) involving
dietary modification and regular physical activity
Outcomes Changes in CVD risk factors (blood pressure, lipid levels, diabetes, obesity)
Maximum follow-up: 30 months
Notes Study period : Not reported
Sources of funding : Not reported
Declared conflicts of interest of the trialists : Director of USV Ltd (marketer of Oral
Anti-Diabeticmarket andCardiovascular diseasesmedications) contributed to the design
of the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information to judge
Allocation concealment (selection bias) Unclear risk Insufficient information to judge
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to judge
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to judge
Selective reporting (reporting bias) Low risk Primary and secondary outcomes were
clearly stated and reported
Other bias Unclear risk Insufficient information to judge
CVD: cardiovascular disease
DBP: diastolic blood pressure
HDL: high density lipoprotein
IGR: impaired glucose regulation
LDL: low density lipoprotein
NCEP-ATP: National cholesterol education program - adult treatment panel
OGTT: oral glucose tolerance test
SBP: systolic blood pressure
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Cezaretto 2012 Control group received some intervention
Jeemon 2012 Non-random allocation
Jiang 2002 Quasi-experimental study
Jiang 2010 Quasi-experimental study
Jordan 2008 Non-random allocation
Joshi 2012 (C) People with CVD at baseline and no relevant outcomes reported
Kelishadi 2010 Non-random allocation
Kelishadi 2011 Non-random allocation
Kelishadi 2012 Non-random allocation
Kozlov 1997 Secondary prevention of CVD
Lafay 2006 No relevant outcome reported
Molazem 2013 Secondary prevention
Moreira 2005 Quasi-experimental study
Naser 2008 Secondary prevention
Pahkala 2013 Participants with congenital heart disease
Prabhakaran 2009 Non-random allocation
Rabiei 2010 Non-random allocation
Sarrafzadegan 2013 Quasi-experimental study
Satpute 2009 Both groups received an intervention
Seligman 2011 Both groups received an intervention
Shahamfar 2010 Secondary prevention
Shehu 2013 Non-random allocation
39Multiple risk factor interventions for primary prevention of cardiovascular disease in low- and middle-income countries (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Singh 2002 Secondary prevention
Siqueira-Catania 2013 Both groups received an intervention
Steinbach 1982 Non-random allocation
Steinbach 1982a Non-random allocation
Steinbach 1984 Non-random allocation
Sun 2013 Non-random allocation
Suwanphan 2009 Non-random allocation
Torres 2011 Non-random allocation
Tsao 2007 Non-random allocation
Tu 1999 Both groups received an intervention
Wang 2002 People with CVD at baseline
Yao 2009 People with CVD at baseline
Zhang 2012 Secondary prevention
Characteristics of studies awaiting assessment [ordered by study ID]
Belenkov 2004a
Methods Full-text article not yet retrieved
Participants
Interventions
Outcomes
Notes
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Belenkov 2004b
Methods Full-text article not yet retrieved
Participants
Interventions
Outcomes
Notes
Chen 2011
Methods Full-text article not yet retrieved
Participants
Interventions
Outcomes
Notes
Granel 1999
Methods Full-text article not yet retrieved
Participants
Interventions
Outcomes
Notes
Marín 2009
Methods Article written in Spanish with no English abstract - awaiting translation
Participants
Interventions
Outcomes
Notes
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Neves 2010
Methods Article written in Portuguese with no English abstract - awaiting translation
Participants
Interventions
Outcomes
Notes
Oganov 2009
Methods Article written in Russian with no English abstract - awaiting translation
Participants
Interventions
Outcomes
Notes
Oganov 2010
Methods Article written in Russian with no English abstract - awaiting translation
Participants
Interventions
Outcomes
Notes
Sans 1993
Methods Article written in Spanish with no English abstract - awaiting translation
Participants
Interventions
Outcomes
Notes
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Stamler 1983
Methods Article written in Russian with no English abstract - awaiting translation
Participants
Interventions
Outcomes
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Multiple risk factor interventions
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cardiovascular event 1 232 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.11, 3.07]
2 Systolic blood pressure, change
from baseline (mmHg)
11 4868 Mean Difference (IV, Random, 95% CI) -6.72 [-9.82, -3.61]
2.1 General population 1 1962 Mean Difference (IV, Random, 95% CI) -3.95 [-5.20, -2.70]
2.2 High risk population 10 2906 Mean Difference (IV, Random, 95% CI) -7.14 [-11.07, -3.21]
3 Systolic blood pressure, by
method of randomisation
11 4868 Mean Difference (IV, Random, 95% CI) -6.72 [-9.82, -3.61]
3.1 Individual 9 3549 Mean Difference (IV, Random, 95% CI) -8.02 [-11.79, -4.24]
3.2 Clustered 2 1319 Mean Difference (IV, Random, 95% CI) -1.65 [-6.52, 3.22]
4 Diastolic blood pressure, change
from baseline (mmHg)
11 4701 Mean Difference (IV, Random, 95% CI) -4.40 [-6.47, -2.34]
4.1 General population 1 1962 Mean Difference (IV, Random, 95% CI) -3.18 [-3.90, -2.46]
4.2 High-risk population 10 2739 Mean Difference (IV, Random, 95% CI) -4.55 [-7.26, -1.85]
5 Diastolic blood pressure, by
method of randomisation
11 4701 Mean Difference (IV, Random, 95% CI) -4.40 [-6.47, -2.34]
5.1 Individual 9 3549 Mean Difference (IV, Random, 95% CI) -5.29 [-7.65, -2.94]
5.2 Clustered 2 1152 Mean Difference (IV, Random, 95% CI) -0.70 [-3.79, 2.40]
6 Body mass index, change from
baseline (kg/m2)
7 2984 Mean Difference (IV, Random, 95% CI) -0.76 [-1.29, -0.22]
6.1 General population 1 1962 Mean Difference (IV, Random, 95% CI) -0.14 [-0.47, 0.19]
6.2 High-risk population 6 1022 Mean Difference (IV, Random, 95% CI) -0.94 [-1.54, -0.33]
7 Waist circumference, change
from baseline (cm).
4 393 Mean Difference (IV, Random, 95% CI) -3.31 [-4.77, -1.86]
7.1 High-risk population 4 393 Mean Difference (IV, Random, 95% CI) -3.31 [-4.77, -1.86]
8 Fasting blood glucose, change
from baseline (mmol/L)
6 2726 Mean Difference (IV, Random, 95% CI) -0.22 [-0.56, 0.13]
8.1 General population 1 1962 Mean Difference (IV, Random, 95% CI) -0.79 [-0.99, -0.59]
8.2 High-risk population 5 764 Mean Difference (IV, Random, 95% CI) -0.08 [-0.27, 0.12]
9 Cholesterol, change from
baseline (mmol/L)
6 Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 HDL-cholesterol 6 824 Mean Difference (IV, Random, 95% CI) 0.03 [-0.01, 0.07]
9.2 LDL-cholesterol 4 544 Mean Difference (IV, Random, 95% CI) -0.13 [-0.53, 0.27]
9.3 Total cholesterol 5 625 Mean Difference (IV, Random, 95% CI) -0.22 [-0.48, 0.04]
10 Triglyceries, change from
baseline (mmol/L)
6 2705 Mean Difference (IV, Random, 95% CI) -0.14 [-0.23, -0.04]
10.1 General population 1 1962 Mean Difference (IV, Random, 95% CI) -0.21 [-0.34, -0.08]
10.2 High-risk population 5 743 Mean Difference (IV, Random, 95% CI) -0.10 [-0.22, 0.01]
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Analysis 1.1. Comparison 1 Multiple risk factor interventions, Outcome 1 Cardiovascular event.
Review: Multiple risk factor interventions for primary prevention of cardiovascular disease in low- and middle-income countries
Comparison: 1 Multiple risk factor interventions
Outcome: 1 Cardiovascular event
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Snehalatha 2008 2/108 4/124 100.0 % 0.57 [ 0.11, 3.07 ]
Total (95% CI) 108 124 100.0 % 0.57 [ 0.11, 3.07 ]
Total events: 2 (Intervention), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Multiple risk factor interventions, Outcome 2 Systolic blood pressure, change
from baseline (mmHg).
Review: Multiple risk factor interventions for primary prevention of cardiovascular disease in low- and middle-income countries
Comparison: 1 Multiple risk factor interventions
Outcome: 2 Systolic blood pressure, change from baseline (mmHg)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 General population
Chao 2012 957 -5.6 (15.1) 1005 -1.65 (13.03) 10.5 % -3.95 [ -5.20, -2.70 ]
Subtotal (95% CI) 957 1005 10.5 % -3.95 [ -5.20, -2.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.19 (P < 0.00001)
2 High risk population
Garcia-Pe a 2001 345 -6.8 (19.83) 338 -3.5 (19.63) 9.7 % -3.30 [ -6.26, -0.34 ]
Sartorelli 2005 40 -0.8 (12.3) 31 3.1 (13) 7.7 % -3.90 [ -9.86, 2.06 ]
Cakir 2006 30 -8.8 (5.2) 30 1.2 (5.3) 9.9 % -10.00 [ -12.66, -7.34 ]
Snehalatha 2008 108 -1 (14.7) 124 -3.2 (14.3) 9.2 % 2.20 [ -1.54, 5.94 ]
M rquez-Celedonio 2009 38 -14.03 (6.91) 43 -3.19 (8.53) 9.5 % -10.84 [ -14.21, -7.47 ]
Jafar 2009 (C) 348 -5.6 (22.9) 326 -6.61 (22.72) 9.4 % 1.01 [ -2.44, 4.46 ]
Mendis 2010 (C) 332 -12.2 (13.82) 313 -8.23 (16.11) 10.0 % -3.97 [ -6.29, -1.65 ]
Hacihasanoglu 2011 40 -25.12 (12.56) 40 -2.5 (13.1) 7.9 % -22.62 [ -28.24, -17.00 ]
Lu 2011 95 -3.49 (17.16) 86 13.77 (21.95) 7.8 % -17.26 [ -23.04, -11.48 ]
Hammad 2011 110 -12.1 (20.1) 89 -6.9 (14.6) 8.5 % -5.20 [ -10.03, -0.37 ]
Subtotal (95% CI) 1486 1420 89.5 % -7.14 [ -11.07, -3.21 ]
Heterogeneity: Tau2 = 35.72; Chi2 = 105.76, df = 9 (P<0.00001); I2 =91%
Test for overall effect: Z = 3.56 (P = 0.00037)
Total (95% CI) 2443 2425 100.0 % -6.72 [ -9.82, -3.61 ]
Heterogeneity: Tau2 = 23.59; Chi2 = 110.90, df = 10 (P<0.00001); I2 =91%
Test for overall effect: Z = 4.24 (P = 0.000023)
Test for subgroup differences: Chi2 = 2.29, df = 1 (P = 0.13), I2 =56%
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Analysis 1.3. Comparison 1 Multiple risk factor interventions, Outcome 3 Systolic blood pressure, by
method of randomisation.
Review: Multiple risk factor interventions for primary prevention of cardiovascular disease in low- and middle-income countries
Comparison: 1 Multiple risk factor interventions
Outcome: 3 Systolic blood pressure, by method of randomisation
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Individual
Garcia-Pe a 2001 345 -6.8 (19.83) 338 -3.5 (19.63) 9.7 % -3.30 [ -6.26, -0.34 ]
Sartorelli 2005 40 -0.8 (12.3) 31 3.1 (13) 7.7 % -3.90 [ -9.86, 2.06 ]
Cakir 2006 30 -8.8 (5.2) 30 1.2 (5.3) 9.9 % -10.00 [ -12.66, -7.34 ]
Snehalatha 2008 108 -1 (14.7) 124 -3.2 (14.3) 9.2 % 2.20 [ -1.54, 5.94 ]
M rquez-Celedonio 2009 38 -14.03 (6.91) 43 -3.19 (8.53) 9.5 % -10.84 [ -14.21, -7.47 ]
Hammad 2011 110 -12.1 (20.1) 89 -6.9 (14.6) 8.5 % -5.20 [ -10.03, -0.37 ]
Lu 2011 95 -3.49 (17.16) 86 13.77 (21.95) 7.8 % -17.26 [ -23.04, -11.48 ]
Hacihasanoglu 2011 40 -25.12 (12.56) 40 -2.5 (13.1) 7.9 % -22.62 [ -28.24, -17.00 ]
Chao 2012 957 -5.6 (15.1) 1005 -1.65 (13.03) 10.5 % -3.95 [ -5.20, -2.70 ]
Subtotal (95% CI) 1763 1786 80.5 % -8.02 [ -11.79, -4.24 ]
Heterogeneity: Tau2 = 28.83; Chi2 = 96.66, df = 8 (P<0.00001); I2 =92%
Test for overall effect: Z = 4.16 (P = 0.000031)
2 Clustered
Jafar 2009 (C) 348 -5.6 (22.9) 326 -6.61 (22.72) 9.4 % 1.01 [ -2.44, 4.46 ]
Mendis 2010 (C) 332 -12.2 (13.82) 313 -8.23 (16.11) 10.0 % -3.97 [ -6.29, -1.65 ]
Subtotal (95% CI) 680 639 19.5 % -1.65 [ -6.52, 3.22 ]
Heterogeneity: Tau2 = 10.15; Chi2 = 5.52, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 0.66 (P = 0.51)
Total (95% CI) 2443 2425 100.0 % -6.72 [ -9.82, -3.61 ]
Heterogeneity: Tau2 = 23.59; Chi2 = 110.90, df = 10 (P<0.00001); I2 =91%
Test for overall effect: Z = 4.24 (P = 0.000023)
Test for subgroup differences: Chi2 = 4.10, df = 1 (P = 0.04), I2 =76%
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Analysis 1.4. Comparison 1 Multiple risk factor interventions, Outcome 4 Diastolic blood pressure, change
from baseline (mmHg).
Review: Multiple risk factor interventions for primary prevention of cardiovascular disease in low- and middle-income countries
Comparison: 1 Multiple risk factor interventions
Outcome: 4 Diastolic blood pressure, change from baseline (mmHg)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 General population
Chao 2012 957 -3.76 (8.75) 1005 -0.58 (7.35) 10.3 % -3.18 [ -3.90, -2.46 ]
Subtotal (95% CI) 957 1005 10.3 % -3.18 [ -3.90, -2.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.70 (P < 0.00001)
2 High-risk population
Garcia-Pe a 2001 345 -3.7 (15.89) 338 0 (15.89) 9.1 % -3.70 [ -6.08, -1.32 ]
Sartorelli 2005 40 -1.3 (8.9) 31 3.5 (7.4) 7.7 % -4.80 [ -8.59, -1.01 ]
Cakir 2006 30 -6.9 (5.3) 30 1.6 (4.6) 9.0 % -8.50 [ -11.01, -5.99 ]
Snehalatha 2008 108 7 (9.7) 124 6.2 (9.9) 9.0 % 0.80 [ -1.73, 3.33 ]
M rquez-Celedonio 2009 38 -11.32 (4.86) 43 -2 (5.75) 9.2 % -9.32 [ -11.63, -7.01 ]
Jafar 2009 (C) 348 -4.8 (12.21) 326 -5.7 (12.22) 9.6 % 0.90 [ -0.95, 2.75 ]
Mendis 2010 (C) 246 -5.73 (8.79) 232 -3.47 (10.34) 9.7 % -2.26 [ -3.99, -0.53 ]
Hammad 2011 110 -7 (12.6) 89 -4.9 (8.1) 8.6 % -2.10 [ -4.99, 0.79 ]
Lu 2011 95 -5.02 (9.34) 86 1.42 (12.12) 8.4 % -6.44 [ -9.62, -3.26 ]
Hacihasanoglu 2011 40 -12 (4.93) 40 -1.7 (4.74) 9.4 % -10.30 [ -12.42, -8.18 ]
Subtotal (95% CI) 1400 1339 89.7 % -4.55 [ -7.26, -1.85 ]
Heterogeneity: Tau2 = 17.28; Chi2 = 115.38, df = 9 (P<0.00001); I2 =92%
Test for overall effect: Z = 3.30 (P = 0.00095)
Total (95% CI) 2357 2344 100.0 % -4.40 [ -6.47, -2.34 ]
Heterogeneity: Tau2 = 10.70; Chi2 = 119.10, df = 10 (P<0.00001); I2 =92%
Test for overall effect: Z = 4.18 (P = 0.000030)
Test for subgroup differences: Chi2 = 0.93, df = 1 (P = 0.34), I2 =0.0%
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Analysis 1.5. Comparison 1 Multiple risk factor interventions, Outcome 5 Diastolic blood pressure, by
method of randomisation.
Review: Multiple risk factor interventions for primary prevention of cardiovascular disease in low- and middle-income countries
Comparison: 1 Multiple risk factor interventions
Outcome: 5 Diastolic blood pressure, by method of randomisation
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Individual
Garcia-Pe a 2001 345 -3.7 (15.89) 338 0 (15.89) 9.1 % -3.70 [ -6.08, -1.32 ]
Sartorelli 2005 40 -1.3 (8.9) 31 3.5 (7.4) 7.7 % -4.80 [ -8.59, -1.01 ]
Cakir 2006 30 -6.9 (5.3) 30 1.6 (4.6) 9.0 % -8.50 [ -11.01, -5.99 ]
Snehalatha 2008 108 7 (9.7) 124 6.2 (9.9) 9.0 % 0.80 [ -1.73, 3.33 ]
M rquez-Celedonio 2009 38 -11.32 (4.86) 43 -2 (5.75) 9.2 % -9.32 [ -11.63, -7.01 ]
Hacihasanoglu 2011 40 -12 (4.93) 40 -1.7 (4.74) 9.4 % -10.30 [ -12.42, -8.18 ]
Lu 2011 95 -5.02 (9.34) 86 1.42 (12.12) 8.4 % -6.44 [ -9.62, -3.26 ]
Hammad 2011 110 -7 (12.6) 89 -4.9 (8.1) 8.6 % -2.10 [ -4.99, 0.79 ]
Chao 2012 957 -3.76 (8.75) 1005 -0.58 (7.35) 10.3 % -3.18 [ -3.90, -2.46 ]
Subtotal (95% CI) 1763 1786 80.7 % -5.29 [ -7.65, -2.94 ]
Heterogeneity: Tau2 = 11.29; Chi2 = 88.93, df = 8 (P<0.00001); I2 =91%
Test for overall effect: Z = 4.40 (P = 0.000011)
2 Clustered
Jafar 2009 (C) 348 -4.8 (12.21) 326 -5.7 (12.22) 9.6 % 0.90 [ -0.95, 2.75 ]
Mendis 2010 (C) 246 -5.73 (8.79) 232 -3.47 (10.34) 9.7 % -2.26 [ -3.99, -0.53 ]
Subtotal (95% CI) 594 558 19.3 % -0.70 [ -3.79, 2.40 ]
Heterogeneity: Tau2 = 4.16; Chi2 = 6.01, df = 1 (P = 0.01); I2 =83%
Test for overall effect: Z = 0.44 (P = 0.66)
Total (95% CI) 2357 2344 100.0 % -4.40 [ -6.47, -2.34 ]
Heterogeneity: Tau2 = 10.70; Chi2 = 119.10, df = 10 (P<0.00001); I2 =92%
Test for overall effect: Z = 4.18 (P = 0.000030)
Test for subgroup differences: Chi2 = 5.36, df = 1 (P = 0.02), I2 =81%
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Analysis 1.6. Comparison 1 Multiple risk factor interventions, Outcome 6 Body mass index, change from
baseline (kg/m2).
Review: Multiple risk factor interventions for primary prevention of cardiovascular disease in low- and middle-income countries
Comparison: 1 Multiple risk factor interventions
Outcome: 6 Body mass index, change from baseline (kg/m2)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 General population
Chao 2012 957 -0.62 (3.86) 1005 -0.48 (3.49) 22.7 % -0.14 [ -0.47, 0.19 ]
Subtotal (95% CI) 957 1005 22.7 % -0.14 [ -0.47, 0.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
2 High-risk population
Cakir 2006 30 -1.5 (0.84) 30 0.13 (0.89) 21.2 % -1.63 [ -2.07, -1.19 ]
Hacihasanoglu 2011 40 -1.36 (2.82) 40 -0.03 (4.15) 8.0 % -1.33 [ -2.88, 0.22 ]
Lu 2011 95 -0.83 (3.61) 86 -0.25 (18.76) 1.6 % -0.58 [ -4.61, 3.45 ]
Mendis 2010 (C) 282 -0.07 (1.64) 267 0.43 (1.75) 23.1 % -0.50 [ -0.78, -0.22 ]
M rquez-Celedonio 2009 38 -1.27 (4.62) 43 -0.89 (5.48) 4.7 % -0.38 [ -2.58, 1.82 ]
Sartorelli 2005 40 -0.9 (1.3) 31 -0.2 (1.3) 18.7 % -0.70 [ -1.31, -0.09 ]
Subtotal (95% CI) 525 497 77.3 % -0.94 [ -1.54, -0.33 ]
Heterogeneity: Tau2 = 0.30; Chi2 = 18.75, df = 5 (P = 0.002); I2 =73%
Test for overall effect: Z = 3.04 (P = 0.0024)
Total (95% CI) 1482 1502 100.0 % -0.76 [ -1.29, -0.22 ]
Heterogeneity: Tau2 = 0.30; Chi2 = 30.34, df = 6 (P = 0.00003); I2 =80%
Test for overall effect: Z = 2.79 (P = 0.0053)
Test for subgroup differences: Chi2 = 5.17, df = 1 (P = 0.02), I2 =81%
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Analysis 1.7. Comparison 1 Multiple risk factor interventions, Outcome 7 Waist circumference, change
from baseline (cm)..
Review: Multiple risk factor interventions for primary prevention of cardiovascular disease in low- and middle-income countries
Comparison: 1 Multiple risk factor interventions
Outcome: 7 Waist circumference, change from baseline (cm).
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk population
Cakir 2006 30 -3.83 (2.32) 30 0.53 (0.43) 42.7 % -4.36 [ -5.20, -3.52 ]
Lu 2011 95 -4.52 (8.81) 86 -1.51 (9.2) 18.9 % -3.01 [ -5.64, -0.38 ]
M rquez-Celedonio 2009 38 -4.47 (10.37) 43 -0.99 (11.71) 7.7 % -3.48 [ -8.29, 1.33 ]
Snehalatha 2008 40 -1.9 (3.7) 31 0.1 (3.3) 30.6 % -2.00 [ -3.63, -0.37 ]
Total (95% CI) 203 190 100.0 % -3.31 [ -4.77, -1.86 ]
Heterogeneity: Tau2 = 1.10; Chi2 = 6.72, df = 3 (P = 0.08); I2 =55%
Test for overall effect: Z = 4.47 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Multiple risk factor interventions, Outcome 8 Fasting blood glucose, change
from baseline (mmol/L).
Review: Multiple risk factor interventions for primary prevention of cardiovascular disease in low- and middle-income countries
Comparison: 1 Multiple risk factor interventions
Outcome: 8 Fasting blood glucose, change from baseline (mmol/L)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 General population
Chao 2012 957 -1.47 (2.11) 1005 -0.68 (2.33) 18.9 % -0.79 [ -0.99, -0.59 ]
Subtotal (95% CI) 957 1005 18.9 % -0.79 [ -0.99, -0.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.88 (P < 0.00001)
2 High-risk population
Hammad 2011 110 -0.73 (1.78) 89 -0.32 (1.44) 15.0 % -0.41 [ -0.86, 0.04 ]
Lu 2011 95 -0.12 (0.45) 86 0.03 (0.77) 19.1 % -0.15 [ -0.34, 0.04 ]
M rquez-Celedonio 2009 38 -0.15 (0.67) 43 -0.05 (1.8) 12.8 % -0.10 [ -0.68, 0.48 ]
Sartorelli 2005 40 0.01 (0.73) 31 0.08 (0.51) 17.7 % -0.07 [ -0.36, 0.22 ]
Snehalatha 2008 124 1 (1.56) 108 0.7 (1.21) 16.5 % 0.30 [ -0.06, 0.66 ]
Subtotal (95% CI) 407 357 81.1 % -0.08 [ -0.27, 0.12 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 6.97, df = 4 (P = 0.14); I2 =43%
Test for overall effect: Z = 0.78 (P = 0.44)
Total (95% CI) 1364 1362 100.0 % -0.22 [ -0.56, 0.13 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 40.32, df = 5 (P<0.00001); I2 =88%
Test for overall effect: Z = 1.24 (P = 0.22)
Test for subgroup differences: Chi2 = 25.21, df = 1 (P = 0.00), I2 =96%
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Analysis 1.9. Comparison 1 Multiple risk factor interventions, Outcome 9 Cholesterol, change from
baseline (mmol/L).
Review: Multiple risk factor interventions for primary prevention of cardiovascular disease in low- and middle-income countries
Comparison: 1 Multiple risk factor interventions
Outcome: 9 Cholesterol, change from baseline (mmol/L)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 HDL-cholesterol
Cakir 2006 30 0.04 (0.13) 30 -0.01 (0.1) 22.7 % 0.05 [ -0.01, 0.11 ]
Hammad 2011 110 0.13 (0.35) 89 0.05 (0.32) 13.4 % 0.08 [ -0.01, 0.17 ]
Lu 2011 95 0.29 (0.28) 86 0.21 (0.31) 14.8 % 0.08 [ -0.01, 0.17 ]
M rquez-Celedonio 2009 38 0.02 (0.24) 43 -0.02 (0.25) 11.0 % 0.04 [ -0.07, 0.15 ]
Sartorelli 2005 40 -0.01 (0.21) 31 0 (0.2) 12.9 % -0.01 [ -0.11, 0.09 ]
Snehalatha 2008 124 0 (0.2) 108 0.03 (0.2) 25.3 % -0.03 [ -0.08, 0.02 ]
Subtotal (95% CI) 437 387 100.0 % 0.03 [ -0.01, 0.07 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 8.53, df = 5 (P = 0.13); I2 =41%
Test for overall effect: Z = 1.39 (P = 0.16)
2 LDL-cholesterol
Cakir 2006 30 -0.75 (0.99) 30 -0.13 (0.4) 22.5 % -0.62 [ -1.00, -0.24 ]
Lu 2011 95 -0.17 (0.65) 86 -0.15 (0.62) 26.6 % -0.02 [ -0.21, 0.17 ]
Sartorelli 2005 40 -0.49 (0.6) 31 -0.11 (0.6) 24.8 % -0.38 [ -0.66, -0.10 ]
Snehalatha 2008 124 0.1 (0.85) 108 -0.3 (0.8) 26.2 % 0.40 [ 0.19, 0.61 ]
Subtotal (95% CI) 289 255 100.0 % -0.13 [ -0.53, 0.27 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 30.75, df = 3 (P<0.00001); I2 =90%
Test for overall effect: Z = 0.66 (P = 0.51)
3 Total cholesterol
Cakir 2006 30 -0.72 (0.91) 30 0.05 (0.5) 18.9 % -0.77 [ -1.14, -0.40 ]
Lu 2011 95 0.07 (0.83) 86 0.21 (0.94) 23.4 % -0.14 [ -0.40, 0.12 ]
M rquez-Celedonio 2009 38 0.05 (0.89) 43 0.05 (0.95) 17.8 % 0.0 [ -0.40, 0.40 ]
Sartorelli 2005 40 -0.52 (1.2) 31 -0.28 (0.6) 16.8 % -0.24 [ -0.67, 0.19 ]
Snehalatha 2008 124 0.2 (0.98) 108 0.2 (1.08) 23.1 % 0.0 [ -0.27, 0.27 ]
Subtotal (95% CI) 327 298 100.0 % -0.22 [ -0.48, 0.04 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 12.36, df = 4 (P = 0.01); I2 =68%
Test for overall effect: Z = 1.63 (P = 0.10)
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Analysis 1.10. Comparison 1 Multiple risk factor interventions, Outcome 10 Triglyceries, change from
baseline (mmol/L).
Review: Multiple risk factor interventions for primary prevention of cardiovascular disease in low- and middle-income countries
Comparison: 1 Multiple risk factor interventions
Outcome: 10 Triglyceries, change from baseline (mmol/L)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 General population
Chao 2012 957 -0.46 (1.35) 1005 -0.25 (1.65) 32.5 % -0.21 [ -0.34, -0.08 ]
Subtotal (95% CI) 957 1005 32.5 % -0.21 [ -0.34, -0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.09 (P = 0.0020)
2 High-risk population
Cakir 2006 30 -0.16 (0.16) 30 -0.13 (0.4) 26.8 % -0.03 [ -0.18, 0.12 ]
Hammad 2011 110 -0.35 (0.61) 89 -0.16 (0.57) 24.5 % -0.19 [ -0.35, -0.03 ]
Lu 2011 95 -0.35 (1.07) 86 -0.09 (0.98) 9.3 % -0.26 [ -0.56, 0.04 ]
Sartorelli 2005 40 -0.05 (0.7) 31 -0.18 (0.8) 6.8 % 0.13 [ -0.23, 0.49 ]
Snehalatha 2008 124 0.1 (14.08) 108 0 (7.44) 0.1 % 0.10 [ -2.75, 2.95 ]
Subtotal (95% CI) 399 344 67.5 % -0.10 [ -0.22, 0.01 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 4.67, df = 4 (P = 0.32); I2 =14%
Test for overall effect: Z = 1.74 (P = 0.082)
Total (95% CI) 1356 1349 100.0 % -0.14 [ -0.23, -0.04 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 6.23, df = 5 (P = 0.28); I2 =20%
Test for overall effect: Z = 2.80 (P = 0.0050)
Test for subgroup differences: Chi2 = 1.39, df = 1 (P = 0.24), I2 =28%
-4 -2 0 2 4
Favours intervention Favours control
A D D I T I O N A L T A B L E S
Table 1. Intervention contents
Dietary advice Weight control /
loss
Exercise / Ad-
vice on Physical
activity
Smoking cessa-
tion
Psychological
aspect of health
Pharmacother-
apy
Avram 2011 X X X
Chao 2012 X X X
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Table 1. Intervention contents (Continued)
Jafar 2009 (C) X X X
Kisioglu 2004 X X X
Lu 2011 X X
Mendis 2010
(C)
X X X X
Sartorelli 2005 X X
Snehalatha 2008 X X
Garcia-Peña
2001
X X X
Cakir 2006 X X X X
Márquez-
Celedonio 2009
X X X
Hammad 2011 X X
Hacihasanoglu
2011
X X X
A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL
#1MeSH descriptor: [Cardiovascular Diseases] explode all trees
#2cardio*
#3cardia*
#4heart*
#5coronary*
#6angina*
#7ventric*
#8myocard*
#9pericard*
#10isch?em*
#11emboli*
#12arrhythmi*
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#13thrombo*
#14atrial next fibrillat*
#15tachycardi*
#16endocardi*
#17(sick next sinus)
#18MeSH descriptor: [Stroke] explode all trees
#19(stroke or stokes)
#20cerebrovasc*
#21cerebral next vascular
#22apoplexy
#23(brain near/2 accident*)
#24((brain* or cerebral or lacunar) near/2 infarct*)
#25MeSH descriptor: [Hypertension] explode all trees
#26hypertensi*
#27(peripheral next arter* next disease*)
#28((high or increased or elevated) near/2 blood pressure)
#29MeSH descriptor: [Hyperlipidemias] explode all trees
#30hyperlipid*
#31hyperlip?emia*
#32hypercholesterol*
#33hypercholester?emia*
#34hyperlipoprotein?emia*
#35hypertriglycerid?emia*
#36MeSH descriptor: [Arteriosclerosis] explode all trees
#37MeSH descriptor: [Cholesterol] explode all trees
#38cholesterol
#39“multiple risk factor*”
#40MeSH descriptor: [Blood Pressure] this term only
#41“blood pressure”
#42#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20
or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or
#39 or #40 or #41
#43MeSH descriptor: [Health Promotion] explode all trees
#44MeSH descriptor: [Health Education] explode all trees
#45MeSH descriptor: [Health Behavior] explode all trees
#46MeSH descriptor: [Counseling] explode all trees
#47MeSH descriptor: [Primary Prevention] this term only
#48(multifactor* near/5 (interven* or prevent*))
#49((lifestyle or life-style or behavio?r*) near/3 (interven* or educat* or advice* or alter* or change* or inform*))
#50(primary near/3 prevent*)
#51(risk factor* near/3 (reduc* or manage* or managing or interven* or program*))
#52(educat* near/3 (program* or patient*))
#53((health* or wellness or weight or diet* or smok*) near/2 (promot* or program* or campaign* or advic* or educat*))
#54(nonpharmacologic* or non-pharmacologic*)
#55((lifestyle or life style or life-style or behavio?r* or risk factor*) near/3 modif*)
#56#43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55
#57#42 and #56
#58MeSH descriptor: [Developing Countries] this term only
#59((developing or “less* developed” or “under developed” or underdeveloped or “middle income” or “low* income” or underserved
or “under served” or deprived or poor*) near (countr* or nation? or population? or world))
#60((developing or “less* developed” or “under developed” or underdeveloped or “middle income” or “low* income”) near (economy
or economies))
#61(low* near (gdp or gnp or “gross domestic” or “gross national”))
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#62(low near/3 middle near/3 countr*)
#63(lmic or lmics or third world or lami countr*)
#64“transitional countr*”
#65MeSH descriptor: [Asia, Southeastern] explode all trees
#66cambodia* or Kampuchea or myanmar or burma or burmese or indonesia* or laos or lao near/1 democratic republic or lao near/2
people or marshall island* or Malaysia* or Philippines or filipino* or Thailand or thai* or Vietnam* or tuvalu or ellice islands
#67MeSH descriptor: [Far East] explode all trees
#68“north korea*” or democratic people* republic near/2 korea or mongolia* or china or chinese
#69MeSH descriptor: [Melanesia] explode all trees
#70fiji* or Papua New Guinea or Vanuatu or Solomon Islands or Timor-Leste or Melanesia*
#71MeSH descriptor: [Micronesia] explode all trees
#72Micronesia* or Kiribati or Palau or Belau or Pelew
#73MeSH descriptor: [Samoa] explode all trees
#74MeSH descriptor: [Tonga] this term only
#75samoa* or tonga* or tuvalu or ellice islands
#76MeSH descriptor: [Asia, Central] explode all trees
#77kyrgyzstan or kyrgyz or kirghizia or kirghiz or tajikistan or tadzhik or tadzhikistan or tajikistan or Kazakhstan or kazakh or turk*
or Uzbekistan
#78MeSH descriptor: [Europe, Eastern] explode all trees
#79Albania* or Jugoslavija* or Yugoslavia* or serbo-croat* or macedonia* or sloven* or kosovo or Moldova* or Ukrain* or Bulgaria*
or belarus or byelarus or belorussia or bosnia* or Montenegro or Romania* or russia* or ussr or soviet or cccp or serbia* or Latvia* or
Lithuania*
#80MeSH descriptor: [Transcaucasia] explode all trees
#81Armenia* or georgia* or Azerbaijan*
#82MeSH descriptor: [West Indies] explode all trees
#83Haiti or Cuba* or Dominica* or Antigua or Barbuda or Jamaica* or Grenad* or St Lucia* or Saint Lucia* or Grenadines
#84MeSH descriptor: [Central America] explode all trees
#85Belize or Costa Rica* or El Salvador or Guatemala* or Hondura* or Nicaragua or Panama*
#86MeSH descriptor: [South America] explode all trees
#87Bolivia* or Argentin* or Brazil* or Chile* or Colombia* or Ecuador* or Guyana* or Paraguay or Peru* or Surinam* or Uruguay or
Venezuela*
#88MeSH descriptor: [Mexico] explode all trees
#89Mexic*
#90MeSH descriptor: [Africa, Eastern] explode all trees
#91Djibouti or Burundi* or Ethiopia* or Kenya* or Rwanda* or Ruanda* or Somali* or Sudan* or Tanzania* or Uganda* or Eritrea*
#92MeSH descriptor: [Africa, Northern] explode all trees
#93Egypt* or Algeria* or Libya* or Morocc* or Tunisia*
#94MeSH descriptor: [Asia, Western] explode all trees
#95Bangladesh* or Bhutan* or Nepal* or india* or Pakistan* or Sri Lanka* or Syria* or gaza* or turk* or Afghan* or Iran* or Iraq* or
jordan* or Leban* or yemen*
#96MeSH descriptor: [Indian Ocean Islands] explode all trees
#97Maldiv* or Madagasca* or Malagasy Republic or Seychelles or comoros or comores or Mauriti* or Agalega Islands
#98MeSH descriptor: [Africa, Western] explode all trees
#99Benin or Dahomey or Burkina Faso or Burkina Fasso or Upper Volta or Gambia* or Ghan* or Gold Coast or Guinea-Bissau or
Portuguese Guinea or Cote d’Ivoire or Ivory Coast or Liberia* or Mali* or Mauritania* or Niger or Nigeria* or Senegal* or Sierra
Leone* or Togo* or Guinea* or Cape Verde*
#100MeSH descriptor: [Africa, Central] explode all trees
#101Central African Republic or Ubangi-Shari or african* or Chad or Cameroon* or congo* or Gabon* or zaire
#102MeSH descriptor: [Africa, Southern] explode all trees
#103Malawi* or Nyasaland or Mozambi* or Portuguese East Africa or Zimbabwe* or Rhodesia* or Lesotho or Basutoland or Swazi*
or Zambia* or Northern Rhodesia* or Angola* or Botswana* or Bechuanaland or Kalahari or Namibia* or South Africa*
#104MeSH descriptor: [Atlantic Islands] explode all trees
#105sao tome near/2 principe
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#106#58 or #59 or #60 or #61 or #62 or #63 or #64 or #65 or #66 or #67 or #68 or #69 or #70 or #71 or #72 or #73 or #74 or #75
or #76 or #77 or #78 or #79 or #80 or #81 or #82 or #83 or #84 or #85 or #86 or #87 or #88 or #89 or #90 or #91 or #92 or #93 or
#94 or #95 or #96 or #97 or #98 or #99 or #100 or #101 or #102 or #103 or #104 or #105
#107#57 and #106
MEDLINE
1. exp Cardiovascular Diseases/
2. cardio*.tw.
3. cardia*.tw.
4. heart*.tw.
5. coronary*.tw.
6. angina*.tw.
7. ventric*.tw.
8. myocard*.tw.
9. pericard*.tw.
10. isch?em*.tw.
11. emboli*.tw.
12. arrhythmi*.tw.
13. thrombo*.tw.
14. atrial fibrillat*.tw.
15. tachycardi*.tw.
16. endocardi*.tw.
17. (sick adj sinus).tw.
18. exp Stroke/
19. (stroke or stokes).tw.
20. cerebrovasc*.tw.
21. cerebral vascular.tw.
22. apoplexy.tw.
23. (brain adj2 accident*).tw.
24. ((brain* or cerebral or lacunar) adj2 infarct*).tw.
25. exp Hypertension/
26. hypertensi*.tw.
27. peripheral arter* disease*.tw.
28. ((high or increased or elevated) adj2 blood pressure).tw.
29. exp Hyperlipidemias/
30. hyperlipid*.tw.
31. hyperlip?emia*.tw.
32. hypercholesterol*.tw.
33. hypercholester?emia*.tw.
34. hyperlipoprotein?emia*.tw.
35. hypertriglycerid?emia*.tw.
36. exp Arteriosclerosis/
37. exp Cholesterol/
38. cholesterol.tw.
39. Blood Pressure/
40. blood pressure.tw.
41. multiple risk factor*.tw.
42. or/1-41
43. exp Health Promotion/
44. exp Health Education/
45. exp Health Behavior/
46. exp Counseling/
58Multiple risk factor interventions for primary prevention of cardiovascular disease in low- and middle-income countries (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
47. Primary Prevention/
48. (multifactor* adj5 (interven* or prevent*)).tw.
49. ((lifestyle or life-style or behavio?r*) adj3 (interven* or educat* or advice* or alter* or change* or inform*)).tw.
50. (primary adj3 prevent*).tw.
51. (risk factor* adj3 (reduc* or manage* or managing or interven* or program*)).tw.
52. (educat* adj3 (program* or patient*)).tw.
53. ((health* or wellness or weight or diet* or smok*) adj2 (promot* or program* or campaign* or advic* or educat*)).tw.
54. (nonpharmacologic* or non-pharmacologic*).tw.
55. ((lifestyle or life style or life-style or behavio?r* or risk factor*) adj3 modif*).tw.
56. or/43-55
57. 42 and 56
58. randomized controlled trial.pt.
59. controlled clinical trial.pt.
60. randomized.ab.
61. placebo.ab.
62. drug therapy.fs.
63. randomly.ab.
64. trial.ab.
65. groups.ab.
66. 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65
67. exp animals/ not humans.sh.
68. 66 not 67
69. 57 and 68
70. Developing Countries.sh,kf.
71. ((developing or less* developed or under developed or underdeveloped or middle income or low* income or underserved or under
served or deprived or poor*) adj (countr* or nation? or population? or world)).ti,ab.
72. ((developing or less* developed or under developed or underdeveloped or middle income or low* income) adj (economy or
economies)).ti,ab.
73. (low* adj (gdp or gnp or gross domestic or gross national)).ti,ab.
74. (low adj3 middle adj3 countr*).ti,ab.
75. (lmic or lmics or third world or lami countr*).ti,ab.
76. transitional countr*.ti,ab.
77. Cambodia/
78. (cambodia* or Kampuchea).cp,in,jw,mp.
79. “Democratic People’s Republic of Korea”/
80. (north korea* or (democratic people* republic adj2 korea)).cp,in,jw,mp.
81. Myanmar/
82. (myanmar or burma or burmese).cp,in,jw,mp.
83. Fiji/
84. fiji*.cp,in,jw,mp.
85. Indonesia/
86. indonesia*.cp,in,jw,mp.
87. Micronesia/
88. (Micronesia* or Kiribati).cp,in,jw,mp.
89. Laos/
90. (laos or (lao adj1 democratic republic) or (lao adj2 people) or marshall island*).cp,in,jw,mp.
91. Mongolia/
92. mongolia*.cp,in,jw,mp.
93. Papua New Guinea/
94. Papua New Guinea.cp,in,jw,mp.
95. Philippines/
96. (Philippines or filipino*).cp,in,jw,mp.
97. samoa/ or “independent state of samoa”/
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98. samoa*.cp,in,jw,mp.
99. Melanesia/
100. (Solomon Islands or Timor-Leste or Melanesia*).cp,in,jw,mp.
101. Tonga/
102. tonga*.cp,in,jw,mp.
103. Vanuatu/
104. Vanuatu.cp,in,jw,mp.
105. Vietnam/
106. Vietnam*.cp,in,jw,mp.
107. exp China/
108. (china or chinese).cp,in,jw,mp.
109. Malaysia/
110. Malaysia*.cp,in,jw,mp.
111. Palau/
112. (Palau or Belau or Pelew).cp,in,jw,mp.
113. Thailand/
114. (Thailand or thai*).cp,in,jw,mp.
115. (tuvalu or ellice islands).cp,in,jw,mp.
116. Kyrgyzstan/
117. (kyrgyzstan or kyrgyz or kirghizia or kirghiz).cp,in,jw,mp.
118. Tajikistan/
119. (tajikistan or tadzhik or tadzhikistan or tajikistan).cp,in,jw,mp.
120. Albania/
121. Albania*.cp,in,jw,mp.
122. Armenia/
123. Armenia*.cp,in,jw,mp.
124. “Georgia (Republic)”/
125. georgia*.cp,in,jw,mp.
126. Yugoslavia/
127. (Jugoslavija* or Yugoslavia* or serbo-croat* or macedonia* or sloven* or kosovo).cp,in,jw,mp.
128. Moldova/
129. Moldova*.cp,in,jw,mp.
130. Ukraine/
131. Ukrain*.cp,in,jw,mp.
132. Uzbekistan/
133. Uzbekistan.cp,in,jw,mp.
134. Azerbaijan/
135. Azerbaijan*.cp,in,jw,mp.
136. “Republic of Belarus”/
137. (belarus or byelarus or belorussia).cp,in,jw,mp.
138. Bosnia-Herzegovina/
139. bosnia*.cp,in,jw,mp.
140. Bulgaria/
141. Bulgaria*.cp,in,jw,mp.
142. Kazakhstan/
143. (Kazakhstan or kazakh).cp,in,jw,mp.
144. Latvia/
145. Latvia*.cp,in,jw,mp.
146. Lithuania/
147. Lithuania*.cp,in,jw,mp.
148. “Macedonia (Republic)”/
149. Macedonia*.cp,in,jw,mp.
150. Montenegro/
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151. Montenegro.cp,in,jw,mp.
152. Romania/
153. Romania*.cp,in,jw,mp.
154. exp Russia/
155. USSR/
156. (russia* or ussr or soviet or cccp).cp,in,jw,mp.
157. Serbia/
158. serbia*.cp,in,jw,mp.
159. Turkey/
160. turk*.cp,in,jw,mp. not animal/
161. Turkmenistan/
162. Haiti/
163. Haiti.cp,in,jw,mp.
164. Belize/
165. Belize.cp,in,jw,mp.
166. Bolivia/
167. Bolivia*.cp,in,jw,mp.
168. El Salvador/
169. El Salvador.cp,in,jw,mp.
170. Guatemala/
171. Guatemala*.cp,in,jw,mp.
172. Guyana/
173. Guyana*.cp,in,jw,mp.
174. Honduras/
175. Hondura*.cp,in,jw,mp.
176. Nicaragua/
177. Nicaragua.cp,in,jw,mp.
178. Paraguay/
179. Paraguay.cp,in,jw,mp.
180. “Antigua and Barbuda”/
181. (Antigua or Barbuda).cp,in,jw,mp.
182. Argentina/
183. Argentin*.cp,in,jw,mp.
184. Brazil/
185. Brazil*.cp,in,jw,mp.
186. Chile/
187. Chile*.cp,in,jw,mp.
188. Colombia/
189. Colombia*.cp,in,jw,mp.
190. Costa Rica/
191. Costa Rica*.cp,in,jw,mp.
192. Cuba/
193. Cuba*.cp,in,jw,mp.
194. Dominica/
195. Dominican Republic/
196. Dominica*.cp,in,jw,mp.
197. Ecuador/
198. Ecuador*.cp,in,jw,mp.
199. Grenada/
200. Grenad*.cp,in,jw,mp.
201. Jamaica/
202. Jamaica*.cp,in,jw,mp.
203. Mexico/
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204. Mexic*.cp,in,jw,mp.
205. exp Panama/
206. Panama*.cp,in,jw,mp.
207. Peru/
208. Peru*.cp,in,jw,mp.
209. Saint Lucia/
210. (St Lucia* or Saint Lucia*).cp,in,jw,mp.
211. “Saint Vincent and the Grenadines”/
212. Grenadines.cp,in,jw,mp.
213. Suriname/
214. Surinam*.cp,in,jw,mp.
215. Uruguay/
216. Uruguay.cp,in,jw,mp.
217. Venezuela/
218. Venezuela*.cp,in,jw,mp.
219. Djibouti/
220. Djibouti.cp,in,jw,mp.
221. Egypt/
222. Egypt*.cp,in,jw,mp.
223. Iraq/
224. Iraq*.cp,in,jw,mp.
225. Morocco/
226. Morocc*.cp,in,jw,mp.
227. Syria/
228. (Syria* or gaza*).cp,in,jw,mp.
229. Yemen/
230. yemen*.cp,in,jw,mp.
231. Algeria/
232. Algeria*.cp,in,jw,mp.
233. Iran/
234. Iran*.cp,in,jw,mp.
235. Jordan/
236. jordan*.cp,in,jw,mp.
237. Lebanon/
238. Leban*.cp,in,jw,mp.
239. Libya/
240. Libya*.cp,in,jw,mp.
241. Tunisia/
242. Tunisia*.cp,in,jw,mp.
243. Afghanistan/
244. Afghan*.cp,in,jw,mp.
245. Bangladesh/
246. Bangladesh*.cp,in,jw,mp.
247. Nepal/
248. Nepal*.cp,in,jw,mp.
249. Bhutan/
250. Bhutan*.cp,in,jw,mp.
251. exp India/
252. india*.cp,in,jw,mp.
253. Pakistan/
254. Pakistan*.cp,in,jw,mp.
255. Sri Lanka/
256. Sri Lanka*.cp,in,jw,mp.
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257. Indian Ocean Islands/
258. Maldiv*.cp,in,jw,mp.
259. Benin/
260. (Benin or Dahomey).cp,in,jw,mp.
261. Burkina Faso/
262. (Burkina Faso or Burkina Fasso or Upper Volta).cp,in,jw,mp.
263. Burundi/
264. Burundi*.cp,in,jw,mp.
265. Central African Republic/
266. (Central African Republic or Ubangi-Shari or african*).cp,in,jw,mp.
267. Chad/
268. Chad.cp,in,jw,mp.
269. Comoros/
270. (comoros or comores).cp,in,jw,mp.
271. “Democratic Republic of the Congo”/
272. (congo* or zaire).cp,in,jw,mp.
273. Eritrea/
274. Eritrea*.cp,in,jw,mp.
275. Ethiopia/
276. Ethiopia*.cp,in,jw,mp.
277. Gambia/
278. Gambia*.cp,in,jw,mp.
279. Guinea/
280. (Guinea* not (New Guinea or Guinea Pig* or Guinea Fowl)).cp,in,jw,mp.
281. Guinea-Bissau/
282. (Guinea-Bissau or Portuguese Guinea).cp,in,jw,mp.
283. Kenya/
284. Kenya*.cp,in,jw,mp.
285. Liberia/
286. Liberia*.cp,in,jw,mp.
287. Madagascar/
288. (Madagasca* or Malagasy Republic).cp,in,jw,mp.
289. Malawi/
290. (Malawi* or Nyasaland).cp,in,jw,mp.
291. Mali/
292. Mali*.cp,in,jw,mp.
293. Mauritania/
294. Mauritania*.cp,in,jw,mp.
295. Mozambique/
296. (Mozambi* or Portuguese East Africa).cp,in,jw,mp.
297. Niger/
298. (Niger not (Aspergillus or Peptococcus or Schizothorax or Cruciferae or Gobius or Lasius or Agelastes or Melanosuchus or radish
or Parastromateus or Orius or Apergillus or Parastromateus or Stomoxys)).cp,in,jw,mp.
299. Rwanda/
300. (Rwanda* or Ruanda*).cp,in,jw,mp.
301. Sierra Leone/
302. Sierra Leone*.cp,in,jw,mp.
303. Somalia/
304. Somali*.cp,in,jw,mp.
305. Tanzania/
306. Tanzania*.cp,in,jw,mp.
307. Togo/
308. Togo*.cp,in,jw,mp.
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309. Uganda/
310. Uganda*.cp,in,jw,mp.
311. Zimbabwe/
312. (Zimbabwe* or Rhodesia*).cp,in,jw,mp.
313. Cameroon/
314. Cameroon*.cp,in,jw,mp.
315. Cape Verde/
316. Cape Verde*.cp,in,jw,mp.
317. Congo/
318. (congo* not ((democratic republic adj3 congo) or congo red or crimean-congo)).cp,in,jw,mp.
319. Cote d’Ivoire/
320. (Cote d’Ivoire or Ivory Coast).cp,in,jw,mp.
321. Ghana/
322. (Ghan* or Gold Coast).cp,in,jw,mp.
323. Lesotho/
324. (Lesotho or Basutoland).cp,in,jw,mp.
325. Nigeria/
326. Nigeria*.cp,in,jw,mp.
327. Atlantic Islands/
328. (sao tome adj2 principe).cp,in,jw,mp.
329. Senegal/
330. Senegal*.cp,in,jw,mp.
331. Sudan/
332. Sudan*.cp,in,jw,mp.
333. Swaziland/
334. Swazi*.cp,in,jw,mp.
335. Zambia/
336. (Zambia* or Northern Rhodesia*).cp,in,jw,mp.
337. Angola/
338. Angola*.cp,in,jw,mp.
339. Botswana/
340. (Botswana* or Bechuanaland or Kalahari).cp,in,jw,mp.
341. Gabon/
342. Gabon*.cp,in,jw,mp.
343. Mauritius/
344. (Mauriti* or Agalega Islands).cp,in,jw,mp.
345. Namibia/
346. Namibia*.cp,in,jw,mp.
347. Seychelles/
348. Seychelles.cp,in,jw,mp.
349. South Africa/
350. South Africa*.cp,in,jw,mp.
351. or/70-350
352. 69 and 351
EMBASE
1. exp cardiovascular disease/
2. cardio*.tw.
3. cardia*.tw.
4. heart*.tw.
5. coronary*.tw.
6. angina*.tw.
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7. ventric*.tw.
8. myocard*.tw.
9. pericard*.tw.
10. isch?em*.tw.
11. emboli*.tw.
12. arrhythmi*.tw.
13. thrombo*.tw.
14. atrial fibrillat*.tw.
15. tachycardi*.tw.
16. endocardi*.tw.
17. (sick adj sinus).tw.
18. exp cerebrovascular disease/
19. (stroke or stokes).tw.
20. cerebrovasc*.tw.
21. cerebral vascular.tw.
22. apoplexy.tw.
23. (brain adj2 accident*).tw.
24. ((brain* or cerebral or lacunar) adj2 infarct*).tw.
25. exp hypertension/
26. hypertensi*.tw.
27. peripheral arter* disease*.tw.
28. ((high or increased or elevated) adj2 blood pressure).tw.
29. exp hyperlipidemia/
30. hyperlipid*.tw.
31. hyperlip?emia*.tw.
32. hypercholesterol*.tw.
33. hypercholester?emia*.tw.
34. hyperlipoprotein?emia*.tw.
35. hypertriglycerid?emia*.tw.
36. exp Arteriosclerosis/
37. exp Cholesterol/
38. cholesterol.tw.
39. Blood Pressure/
40. blood pressure.tw.
41. multiple risk factor*.tw.
42. or/1-41
43. exp health education/
44. exp health behavior/
45. exp counseling/
46. primary prevention/
47. (multifactor* adj5 (interven* or prevent*)).tw.
48. ((lifestyle or life-style or behavio?r*) adj3 (interven* or educat* or advice* or alter* or change* or inform*)).tw.
49. (primary adj3 prevent*).tw.
50. (risk factor* adj3 (reduc* or manage* or managing or interven* or program*)).tw.
51. (educat* adj3 (program* or patient*)).tw.
52. ((health* or wellness or weight or diet* or smok*) adj2 (promot* or program* or campaign* or advic* or educat*)).tw.
53. (nonpharmacologic* or non-pharmacologic*).tw.
54. ((lifestyle or life style or life-style or behavio?r* or risk factor*) adj3 modif*).tw.
55. or/43-54
56. 42 and 55
57. random$.tw.
58. factorial$.tw.
59. crossover$.tw.
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60. cross over$.tw.
61. cross-over$.tw.
62. placebo$.tw.
63. (doubl$ adj blind$).tw.
64. (singl$ adj blind$).tw.
65. assign$.tw.
66. allocat$.tw.
67. volunteer$.tw.
68. crossover procedure/
69. double blind procedure/
70. randomized controlled trial/
71. single blind procedure/
72. 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71
73. (animal/ or nonhuman/) not human/
74. 72 not 73
75. 56 and 74
76. developing country.sh,hw.
77. ((developing or less* developed or under developed or underdeveloped or middle income or low* income or underserved or under
served or deprived or poor*) adj (countr* or nation? or population? or world)).ti,ab.
78. ((developing or less* developed or under developed or underdeveloped or middle income or low* income) adj (economy or
economies)).ti,ab.
79. (low* adj (gdp or gnp or gross domestic or gross national)).ti,ab.
80. (low adj3 middle adj3 countr*).ti,ab.
81. (lmic or lmics or third world or lami countr*).ti,ab.
82. transitional countr*.ti,ab.
83. Cambodia/
84. (cambodia* or Kampuchea).cp,in,jw,mp.
85. “Democratic People’s Republic of Korea”/
86. (north korea* or (democratic people* republic adj2 korea)).cp,in,jw,mp.
87. Myanmar/
88. (myanmar or burma or burmese).cp,in,jw,mp.
89. Fiji/
90. fiji*.cp,in,jw,mp.
91. Indonesia/
92. indonesia*.cp,in,jw,mp.
93. Micronesia/
94. (Micronesia* or Kiribati).cp,in,jw,mp.
95. Laos/
96. (laos or (lao adj1 democratic republic) or (lao adj2 people) or marshall island*).cp,in,jw,mp.
97. Mongolia/
98. mongolia*.cp,in,jw,mp.
99. Papua New Guinea/
100. Papua New Guinea.cp,in,jw,mp.
101. Philippines/
102. (Philippines or filipino*).cp,in,jw,mp.
103. samoa/ or “independent state of samoa”/
104. samoa*.cp,in,jw,mp.
105. Melanesia/
106. (Solomon Islands or Timor-Leste or Melanesia*).cp,in,jw,mp.
107. Tonga/
108. tonga*.cp,in,jw,mp.
109. Vanuatu/
110. Vanuatu.cp,in,jw,mp.
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111. Vietnam/
112. Vietnam*.cp,in,jw,mp.
113. exp China/
114. (china or chinese).cp,in,jw,mp.
115. Malaysia/
116. Malaysia*.cp,in,jw,mp.
117. Palau/
118. (Palau or Belau or Pelew).cp,in,jw,mp.
119. Thailand/
120. (Thailand or thai*).cp,in,jw,mp.
121. (tuvalu or ellice islands).cp,in,jw,mp.
122. Kyrgyzstan/
123. (kyrgyzstan or kyrgyz or kirghizia or kirghiz).cp,in,jw,mp.
124. Tajikistan/
125. (tajikistan or tadzhik or tadzhikistan or tajikistan).cp,in,jw,mp.
126. Albania/
127. Albania*.cp,in,jw,mp.
128. Armenia/
129. Armenia*.cp,in,jw,mp.
130. “Georgia (Republic)”/
131. georgia*.cp,in,jw,mp.
132. Yugoslavia/
133. (Jugoslavija* or Yugoslavia* or serbo-croat* or macedonia* or sloven* or kosovo).cp,in,jw,mp.
134. Moldova/
135. Moldova*.cp,in,jw,mp.
136. Ukraine/
137. Ukrain*.cp,in,jw,mp.
138. Uzbekistan/
139. Uzbekistan.cp,in,jw,mp.
140. Azerbaijan/
141. Azerbaijan*.cp,in,jw,mp.
142. “Republic of Belarus”/
143. (belarus or byelarus or belorussia).cp,in,jw,mp.
144. Bosnia-Herzegovina/
145. bosnia*.cp,in,jw,mp.
146. Bulgaria/
147. Bulgaria*.cp,in,jw,mp.
148. Kazakhstan/
149. (Kazakhstan or kazakh).cp,in,jw,mp.
150. Latvia/
151. Latvia*.cp,in,jw,mp.
152. Lithuania/
153. Lithuania*.cp,in,jw,mp.
154. “Macedonia (Republic)”/
155. Macedonia*.cp,in,jw,mp.
156. Montenegro/
157. Montenegro.cp,in,jw,mp.
158. Romania/
159. Romania*.cp,in,jw,mp.
160. exp Russia/
161. USSR/
162. (russia* or ussr or soviet or cccp).cp,in,jw,mp.
163. Serbia/
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164. serbia*.cp,in,jw,mp.
165. Turkey/
166. turk*.cp,in,jw,mp. not animal/
167. Turkmenistan/
168. Haiti/
169. Haiti.cp,in,jw,mp.
170. Belize/
171. Belize.cp,in,jw,mp.
172. Bolivia/
173. Bolivia*.cp,in,jw,mp.
174. El Salvador/
175. El Salvador.cp,in,jw,mp.
176. Guatemala/
177. Guatemala*.cp,in,jw,mp.
178. Guyana/
179. Guyana*.cp,in,jw,mp.
180. Honduras/
181. Hondura*.cp,in,jw,mp.
182. Nicaragua/
183. Nicaragua.cp,in,jw,mp.
184. Paraguay/
185. Paraguay.cp,in,jw,mp.
186. “Antigua and Barbuda”/
187. (Antigua or Barbuda).cp,in,jw,mp.
188. Argentina/
189. Argentin*.cp,in,jw,mp.
190. Brazil/
191. Brazil*.cp,in,jw,mp.
192. Chile/
193. Chile*.cp,in,jw,mp.
194. Colombia/
195. Colombia*.cp,in,jw,mp.
196. Costa Rica/
197. Costa Rica*.cp,in,jw,mp.
198. Cuba/
199. Cuba*.cp,in,jw,mp.
200. Dominica/
201. Dominican Republic/
202. Dominica*.cp,in,jw,mp.
203. Ecuador/
204. Ecuador*.cp,in,jw,mp.
205. Grenada/
206. Grenad*.cp,in,jw,mp.
207. Jamaica/
208. Jamaica*.cp,in,jw,mp.
209. Mexico/
210. Mexic*.cp,in,jw,mp.
211. exp Panama/
212. Panama*.cp,in,jw,mp.
213. Peru/
214. Peru*.cp,in,jw,mp.
215. Saint Lucia/
216. (St Lucia* or Saint Lucia*).cp,in,jw,mp.
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217. “Saint Vincent and the Grenadines”/
218. Grenadines.cp,in,jw,mp.
219. Suriname/
220. Surinam*.cp,in,jw,mp.
221. Uruguay/
222. Uruguay.cp,in,jw,mp.
223. Venezuela/
224. Venezuela*.cp,in,jw,mp.
225. Djibouti/
226. Djibouti.cp,in,jw,mp.
227. Egypt/
228. Egypt*.cp,in,jw,mp.
229. Iraq/
230. Iraq*.cp,in,jw,mp.
231. Morocco/
232. Morocc*.cp,in,jw,mp.
233. Syria/
234. (Syria* or gaza*).cp,in,jw,mp.
235. Yemen/
236. yemen*.cp,in,jw,mp.
237. Algeria/
238. Algeria*.cp,in,jw,mp.
239. Iran/
240. Iran*.cp,in,jw,mp.
241. Jordan/
242. jordan*.cp,in,jw,mp.
243. Lebanon/
244. Leban*.cp,in,jw,mp.
245. Libya/
246. Libya*.cp,in,jw,mp.
247. Tunisia/
248. Tunisia*.cp,in,jw,mp.
249. Afghanistan/
250. Afghan*.cp,in,jw,mp.
251. Bangladesh/
252. Bangladesh*.cp,in,jw,mp.
253. Nepal/
254. Nepal*.cp,in,jw,mp.
255. Bhutan/
256. Bhutan*.cp,in,jw,mp.
257. exp India/
258. india*.cp,in,jw,mp.
259. Pakistan/
260. Pakistan*.cp,in,jw,mp.
261. Sri Lanka/
262. Sri Lanka*.cp,in,jw,mp.
263. Indian Ocean Islands/
264. Maldiv*.cp,in,jw,mp.
265. Benin/
266. (Benin or Dahomey).cp,in,jw,mp.
267. Burkina Faso/
268. (Burkina Faso or Burkina Fasso or Upper Volta).cp,in,jw,mp.
269. Burundi/
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270. Burundi*.cp,in,jw,mp.
271. Central African Republic/
272. (Central African Republic or Ubangi-Shari or african*).cp,in,jw,mp.
273. Chad/
274. Chad.cp,in,jw,mp.
275. Comoros/
276. (comoros or comores).cp,in,jw,mp.
277. “Democratic Republic of the Congo”/
278. (congo* or zaire).cp,in,jw,mp.
279. Eritrea/
280. Eritrea*.cp,in,jw,mp.
281. Ethiopia/
282. Ethiopia*.cp,in,jw,mp.
283. Gambia/
284. Gambia*.cp,in,jw,mp.
285. Guinea/
286. (Guinea* not (New Guinea or Guinea Pig* or Guinea Fowl)).cp,in,jw,mp.
287. Guinea-Bissau/
288. (Guinea-Bissau or Portuguese Guinea).cp,in,jw,mp.
289. Kenya/
290. Kenya*.cp,in,jw,mp.
291. Liberia/
292. Liberia*.cp,in,jw,mp.
293. Madagascar/
294. (Madagasca* or Malagasy Republic).cp,in,jw,mp.
295. Malawi/
296. (Malawi* or Nyasaland).cp,in,jw,mp.
297. Mali/
298. Mali*.cp,in,jw,mp.
299. Mauritania/
300. Mauritania*.cp,in,jw,mp.
301. Mozambique/
302. (Mozambi* or Portuguese East Africa).cp,in,jw,mp.
303. Niger/
304. (Niger not (Aspergillus or Peptococcus or Schizothorax or Cruciferae or Gobius or Lasius or Agelastes or Melanosuchus or radish
or Parastromateus or Orius or Apergillus or Parastromateus or Stomoxys)).cp,in,jw,mp.
305. Rwanda/
306. (Rwanda* or Ruanda*).cp,in,jw,mp.
307. Sierra Leone/
308. Sierra Leone*.cp,in,jw,mp.
309. Somalia/
310. Somali*.cp,in,jw,mp.
311. Tanzania/
312. Tanzania*.cp,in,jw,mp.
313. Togo/
314. Togo*.cp,in,jw,mp.
315. Uganda/
316. Uganda*.cp,in,jw,mp.
317. Zimbabwe/
318. (Zimbabwe* or Rhodesia*).cp,in,jw,mp.
319. Cameroon/
320. Cameroon*.cp,in,jw,mp.
321. Cape Verde/
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322. Cape Verde*.cp,in,jw,mp.
323. Congo/
324. (congo* not ((democratic republic adj3 congo) or congo red or crimean-congo)).cp,in,jw,mp.
325. Cote d’Ivoire/
326. (Cote d’Ivoire or Ivory Coast).cp,in,jw,mp.
327. Ghana/
328. (Ghan* or Gold Coast).cp,in,jw,mp.
329. Lesotho/
330. (Lesotho or Basutoland).cp,in,jw,mp.
331. Nigeria/
332. Nigeria*.cp,in,jw,mp.
333. Atlantic Islands/
334. (sao tome adj2 principe).cp,in,jw,mp.
335. Senegal/
336. Senegal*.cp,in,jw,mp.
337. Sudan/
338. Sudan*.cp,in,jw,mp.
339. Swaziland/
340. Swazi*.cp,in,jw,mp.
341. Zambia/
342. (Zambia* or Northern Rhodesia*).cp,in,jw,mp.
343. Angola/
344. Angola*.cp,in,jw,mp.
345. Botswana/
346. (Botswana* or Bechuanaland or Kalahari).cp,in,jw,mp.
347. Gabon/
348. Gabon*.cp,in,jw,mp.
349. Mauritius/
350. (Mauriti* or Agalega Islands).cp,in,jw,mp.
351. Namibia/
352. Namibia*.cp,in,jw,mp.
353. Seychelles/
354. Seychelles.cp,in,jw,mp.
355. South Africa/
356. South Africa*.cp,in,jw,mp.
357. or/76-356
358. 75 and 357
359. limit 358 to embase
Web of Science
# 34 #33 AND #19
# 33 #32 OR #31 OR #30 OR #29 OR #28 OR #27 OR #26 OR #25 OR #24 OR #23 OR #22 OR #21 OR #20
# 32 TS=(Central African Republic or Ubangi-Shari or african* or Chad or Cameroon* or congo* or Gabon* or zaire OR Malawi*
or Nyasaland or Mozambi* or Portuguese East Africa or Zimbabwe* or Rhodesia* or Lesotho or Basutoland or Swazi* or Zambia* or
Northern Rhodesia* or Angola* or Botswana* or Bechuanaland or Kalahari or Namibia* or South Africa* OR sao tome)
# 31 TS=(Benin or Dahomey or Burkina Faso or Burkina Fasso or Upper Volta or Gambia* or Ghan* or Gold Coast or Guinea-Bissau
or Portuguese Guinea or Cote d’Ivoire or Ivory Coast or Liberia* or Mali* or Mauritania* or Niger or Nigeria* or Senegal* or Sierra
Leone* or Togo* or Guinea* or Cape Verde*)
# 30 TS=(Mexic* OR Djibouti or Burundi* or Ethiopia* or Kenya* or Rwanda* or Ruanda* or Somali* or Sudan* or Tanzania* or
Uganda* or Eritrea* OR Egypt* or Algeria* or Libya* or Morocc* or Tunisia* OR Bangladesh* or Bhutan* or Nepal* or india* or
Pakistan* or Sri Lanka* or Syria* or gaza* or turk* or Afghan* or Iran* or Iraq* or jordan* or Leban* or yemen* OR Maldiv* or
Madagasca* or Malagasy Republic or Seychelles or comoros or comores or Mauriti* or Agalega Islands)
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# 29 TS=(Armenia* or georgia* or Azerbaijan* OR Haiti or Cuba* or Dominica* or Antigua or Barbuda or Jamaica* or Grenad* or St
Lucia* or Saint Lucia* or Grenadines OR Belize or Costa Rica* or El Salvador or Guatemala* or Hondura* or Nicaragua or Panama*
OR Bolivia* or Argentin* or Brazil* or Chile* or Colombia* or Ecuador* or Guyana* or Paraguay or Peru* or Surinam* or Uruguay
or Venezuela*)
# 28 TS=(kyrgyzstan or kyrgyz or kirghizia or kirghiz or tajikistan or tadzhik or tadzhikistan or tajikistan or Kazakhstan or kazakh or
turk* or Uzbekistan OR Albania* or Jugoslavija* or Yugoslavia* or serbo-croat* or macedonia* or sloven* or kosovo or Moldova* or
Ukrain* or Bulgaria* or belarus or byelarus or belorussia or bosnia* or Montenegro or Romania* or russia* or ussr or soviet or cccp or
serbia* or Latvia* or Lithuania*)
# 27 TS=(korea* or mongolia* or china or chinese OR fiji* or Papua New Guinea or Vanuatu or Solomon Islands or Timor-Leste or
Melanesia* OR Micronesia* or Kiribati or Palau or Belau or Pelew OR samoa* or tonga* or tuvalu or ellice islands)
# 26 TS=(cambodia* or Kampuchea or myanmar or burma or burmese or indonesia* or laos or lao democratic republic or lao people
or marshall island* or Malaysia* or Philippines or filipino* or Thailand or thai* or Vietnam* or tuvalu or ellice islands )
# 25 TS=(transitional countr*)
# 24 TS=(lmic or lmics or third world or lami countr*)
# 23 TS=(low near/3 middle near/3 countr*)
# 22 TS=(low* NEAR (gdp or gnp or “gross domestic” or “gross national”))
# 21 TS=((developing or “less* developed” or “under developed” or underdeveloped or “middle income” or “low* income”) NEAR
(economy or economies))
# 20TS=((developing or “less* developed” or “under developed” or underdeveloped or “middle income” or “low* income” or underserved
or “under served” or deprived or poor*) NEAR (countr* or nation? or population? or world))
# 19 #18 AND #17
# 18 TS=(random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*)
# 17 #16 AND #8
# 16 #15 OR #14 OR #13 OR #12 OR #11 OR #10 OR #9
# 15 TS=((lifestyle or life style or life-style or behavio?r* or risk factor*) SAME modif*)
# 14 TS=(nonpharmacologic* or non-pharmacologic*)
# 13 TS=((health* or wellness or weight or diet* or smok*) NEAR/2 (promot* or program* or campaign* or advic* or educat*))
# 12 TS=(educat* NEAR/3 (program* or patient*))
# 11 TS=(risk NEAR/2 factor* NEAR/3 (reduc* or manage* or managing or interven* or program*))
# 10 TS=((lifestyle or life-style or behavio?r*) NEAR/3 (interven* or educat* or advice* or alter* or change* or inform*))
# 9 TS=((multifactor* NEAR/5 (interven* or prevent*)) OR (primary NEAR/3 prevent*))
# 8 #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
# 7 TS=(hyperlipid* OR hyperlip?emia*OR hypercholesterol*OR hypercholester?emia*OR hyperlipoprotein?emia*OR hypertriglyc-
erid?emia*)
# 6 TS=(“high blood pressure”)
# 5 TS=(hypertensi* OR “peripheral arter* disease*”)
# 4 TS=(stroke OR stokes OR cerebrovasc* OR cerebral OR apoplexy OR (brain SAME accident*) OR (brain SAME infarct*))
# 3 TS=(“atrial fibrillat*” OR tachycardi* OR endocardi*)
# 2 TS=(pericard* OR isch?em* OR emboli* OR arrhythmi* OR thrombo*)
# 1 TS=(cardio* OR cardia* OR heart* OR coronary* OR angina* OR ventric* OR myocard*)
LILACS
cardio$ or cardia$ or heart$ or coronary or angina$ or myocard$ or ischem$ or ischaem$ or hypertens$ or hyperlipid$ or cholesterol
or “risk factor$” [Words] and “primary prevent$” or “health intervent$” or “health educat$” or “lifestyle modif$” [Words] and trial or
random$ or control$ [Words]
Global Health
1. exp cardiovascular diseases/
2. cardio*.tw.
3. cardia*.tw.
4. heart*.tw.
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5. coronary*.tw.
6. angina*.tw.
7. ventric*.tw.
8. myocard*.tw.
9. pericard*.tw.
10. isch?em*.tw.
11. emboli*.tw.
12. arrhythmi*.tw.
13. thrombo*.tw.
14. atrial fibrillat*.tw.
15. tachycardi*.tw.
16. endocardi*.tw.
17. (sick adj sinus).tw.
18. stroke/
19. (stroke or stokes).tw.
20. cerebrovasc*.tw.
21. cerebral vascular.tw.
22. apoplexy.tw.
23. (brain adj2 accident*).tw.
24. ((brain* or cerebral or lacunar) adj2 infarct*).tw.
25. exp hypertension/
26. hypertensi*.tw.
27. peripheral arter* disease*.tw.
28. ((high or increased or elevated) adj2 blood pressure).tw.
29. exp hyperlipaemia/
30. hyperlipid*.tw.
31. hyperlip?emia*.tw.
32. hypercholesterol*.tw.
33. hypercholester?emia*.tw.
34. hyperlipoprotein?emia*.tw.
35. hypertriglycerid?emia*.tw.
36. exp atherosclerosis/
37. cholesterol/
38. cholesterol.tw.
39. blood pressure/
40. blood pressure.tw.
41. multiple risk factor*.tw.
42. or/1-41
43. health promotion/
44. health education/
45. health behaviour/
46. exp counselling/
47. exp prevention/
48. (multifactor* adj5 (interven* or prevent*)).tw.
49. ((lifestyle or life-style or behavio?r*) adj3 (interven* or educat* or advice* or alter* or change* or inform*)).tw.
50. (primary adj3 prevent*).tw.
51. (risk factor* adj3 (reduc* or manage* or managing or interven* or program*)).tw.
52. (educat* adj3 (program* or patient*)).tw.
53. ((health* or wellness or weight or diet* or smok*) adj2 (promot* or program* or campaign* or advic* or educat*)).tw.
54. (nonpharmacologic* or non-pharmacologic*).tw.
55. ((lifestyle or life style or life-style or behavio?r* or risk factor*) adj3 modif*).tw.
56. or/43-55
57. 42 and 56
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58. random*.tw.
59. trial*.tw.
60. placebo*.tw.
61. groups.tw.
62. control*.tw.
63. or/58-62
64. exp animals/ not man/
65. 63 not 64
66. 57 and 65
67. exp developing countries/
68. ((developing or less* developed or under developed or underdeveloped or middle income or low* income or underserved or under
served or deprived or poor*) adj (countr* or nation? or population? or world)).ti,ab.
69. ((developing or less* developed or under developed or underdeveloped or middle income or low* income) adj (economy or
economies)).ti,ab.
70. (low* adj (gdp or gnp or gross domestic or gross national)).ti,ab.
71. (low adj3 middle adj3 countr*).ti,ab.
72. (lmic or lmics or third world or lami countr*).ti,ab.
73. transitional countr*.ti,ab.
74. (cambodia* or Kampuchea or north korea* or (democratic people* republic adj2 korea) or myanmar or burma or burmese or fiji*
or indonesia* or micronesia* or kiribati or laos or (lao adj1 democratic republic) or (lao adj2 people) or marshall island*).cp,in,jx,tw.
75. (mongolia* or Papua New Guinea or Philippines or filipino* or samoa* or Solomon Islands or Timor-Leste or Melanesia* or
tonga* or vanuatu or vietnam* or china or chinese or malaysia* or palau or belau or pelew or Thailand or thai* or tuvalu or ellice
islands).cp,in,jx,tw.
76. (kyrgyzstan or kyrgyz or kirghizia or kirghiz or tajikistan or tadzhik or tadzhikistan or tajikistan or albania* or armenia* or georgia*
or Jugoslavija* or Yugoslavia* or serbo-croat* or macedonia* or sloven* or kosovo or moldova* or ukrain* or Uzbekistan or Azerbaijan*
or belarus or byelarus or belorussia or bosnia*).cp,in,jx,tw.
77. (Bulgaria* or Kazakhstan or kazakh or latvia* or lithuania* or macedonia* or montenegro or romania* or russia* or ussr or soviet
or cccp or serbia* or turk*).cp,in,jx,tw.
78. (haiti or belize or bolivia* or el salvador or guatemala* or guyana* or hondura* or nicaragua or paraguay or antigua or bar-
buda).cp,in,jx,tw.
79. (Argentin* or brazil* or chile* or colombia* or costa rica* or cuba* or dominica* or ecuador* or grenad* or jamaica* or mexic*
or panama* or peru* or st lucia* or saint lucia* or grenadines or surinam* or uruguay or venezuela* or djibouti or egypt* or iraq* or
morocc*).cp,in,jx,tw.
80. (Syria* or gaza* or yemen* or algeria* or iran* or jordan* or leban* or libya* or tunisia* or afghan* or bangladesh* or nepal* or
bhutan* or india* or pakistan* or sri lanka* or maldiv* or benin or dahomey or brukina faso or burkina fasso or upper volta or burundi*
or Central African Republic or Ubangi-Shari or african* or chad or comoros or comores or congo* or zaire or eritrea*).cp,in,jx,tw.
81. ((Ethiopia* or gambia* or Guinea* or Guinea-Bissau or Portuguese Guinea or kenya* or liberia* or Madagasca* or Malagasy
Republic or malawi* or nyasaland or mali* or mauritania* or mozambi* or portuguese east africa) not (New Guinea or Guinea Pig* or
Guinea Fowl)).cp,in,jx,tw.
82. (Niger not (Aspergillus or Peptococcus or Schizothorax or Cruciferae or Gobius or Lasius or Agelastes or Melanosuchus or radish
or Parastromateus or Orius or Apergillus or Parastromateus or Stomoxys)).cp,in,jx,tw.
83. ((Rwanda* or Ruanda* or sierra leone* or somali* or tanzania* or togo* or uganda* or zimbabwe* or rhodesia* or cameroon* or
cape verde* or congo*) not ((democratic republic adj3 congo) or congo red or crimean-congo)).cp,in,jx,tw.
84. (((Cote d’Ivoire or Ivory Coast or ghan* or gold coast or Lesotho or Basutoland or nigeria* or sao tome) adj2 principe) or senegal*
or sudan* or swazi* or zambia* or northern rhodesia* or angola* or botswana* or Bechuanaland or Kalahari or gabon* or Mauriti* or
Agalega Islands or namibia* or seychelles or south africa*).cp,in,jx,tw.
85. or/67-84
86. 66 and 85
ELDIS
(cardio* or heart*) and (risk* or interven* or educat* or program* or prevent*) and (random* or trial*)
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C O N T R I B U T I O N S O F A U T H O R S
OAU and LH screened titles and abstracts and assessed studies for formal inclusion and exclusion. OAU and LH abstracted data and
assessed methodological rigour. OAU analysed the data, which were checked by LH. OAU wrote the first draft of the review and all
review authors contributed to later drafts.
D E C L A R A T I O N S O F I N T E R E S T
OAU: None known.
LH: None known.
KR: None known.
FT: None known.
SE: Research is supported by a grant from UK Department for International Development.
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S O U R C E S O F S U P P O R T
Internal sources
• Warwick Medical School, UK.
• Liverpool School of Tropical Medicine, UK.
• London School of Hygiene and Tropical Medicine, UK.
• Center for Evidence-based Health Care, Stellenbosch University, South Africa.
External sources
• NIHR Cochrane Programme Grant, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Assessment of risk of bias in included studies
Deleted: “Blinding of participants and personnel.”
Dealing with missing data
Deleted: “Where this is not possible and the missing data are thought to introduce serious bias, we will explore the impact of including such
studies in the overall assessment of results by a sensitivity analysis.”
Data synthesis
Deleted:“We will express time-to-event outcomes or generic inverse variance outcomes, such as survival time and time to development of
cardiovascular disease, as the log hazard ratio and 95% CI.
When studies cannot be combined for meta-analysis due to diversity of interventions, we will conduct narrative syntheses and display the results
of individual studies graphically to enable a more succinct summary of the evidence. We will also narratively describe skewed data reported as
medians and interquartile ranges.”
Subgroup analysis and investigation of heterogeneity
Deleted: “Evidence of prescribed drug treatment (prescribed medication during trial and no prescribed medication or drug treatment not
stated).
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Co-morbidity (diabetes, hypertension, obesity, no co-morbidity).
Age.
Sex.
Age of trial (publication year: before 2000 versus after 2000).
We will use meta-regression methods to examine the effects of baseline mean values for age, sex and blood pressure, if sufficiently reported.”
The planned subgroup analysis for low-income vs low-and middle-income countries could not be performed because all the studies
were from middle-income countries.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Developing Countries; Cardiovascular Diseases [∗prevention & control]; Diabetes Mellitus, Type 2 [therapy]; Diet; Exercise; Health
Promotion [∗methods]; Hypertension [therapy]; Primary Prevention [∗methods]; Randomized Controlled Trials as Topic; Risk Factors
MeSH check words
Humans
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